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The transcription factor SRY (sex determining region Y)-box 4 (SOX4) 
regulates embryonic development and has been shown to drive the progression 
and metastasis of multiple solid cancer types. A common transcriptional target of 
SOX4 that mediates its effects in multiple cancer types has yet to be identified. 
Through a systematic molecular and genomic approach, we identify the 
transmembrane protein 2 (TMEM2) gene as a direct transcriptional target of 
SOX4. 
TMEM2 is transcriptionally activated by SOX4 in both breast cancer and 
lung adenocarcinoma cells and mediates pro-invasive and pro-migratory effects 
of SOX4. TMEM2, like SOX4, is sufficient to promote breast cancer metastatic 
colonization and its expression in high-risk primary breast tumors associates with 
metastatic relapse likelihood. Interestingly, independent studies wherein SOX4 or 
TMEM2 have been genetically inactivated have resulted in similar cardiac 
developmental defects, suggesting that TMEM2, in addition to mediating the 
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PART I: BREAST CANCER 
 
Breast cancer is the most common cancer in women and the second most 
common cancer across the entire population of the United States (The National 
Cancer Institutes Surveillance, Epidemiology, and End Results (SEER) database 
of 2015) (Fig. 1.1). It is estimated that 12 % of women in the United States will 
develop invasive breast cancer during their lifetime, which is estimated to be 
responsible for 3% of all female patients’ death from cancer. Most patients die 
from metastatic disease (Gupta and Massagué, 2006), which is the spread of 
cancer cells from a primary tumor to distal organs and the growth of metastatic 
colonies in these organs. 
 
Figure 1.1 Breast cancer as the most common cancer in women 
The National Cancer Institutes SEER (Surveillance, Epidemiology, and End 
Results) database of 2015 estimates 231,840 new cases of breast cancer and 
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1. Breast Cancer (Female) 231,840 40,290
2. Lung and Bronchus Cancer 221,200 158,040
3. Prostate Cancer 220,800 27,540
4. Colon and Rectum Cancer 132,700 49,700
5. Bladder Cancer 74,000 16,000
6. Melanoma of the Skin 73,870 9,940
7. Non-Hodgkin Lymphoma 71,850 19,790
8. Thyroid Cancer 62,450 1,950
9. Kidney and Renal PelvisCancer 61,560 14,080




Most cancers by incidence such as skin, colon, prostate, lung, or breast 
cancer originate from epithelial tissues (Blanpain, 2013). Breast cancer arises 
from the mammary tissue, which consists of lobules (milk-producing glands), 
ducts (tubes that bring milk from the lobules to the nipple), and stroma (connective 
fatty tissue that surrounds lobules and vessels) (Fig. 1.2). Breast cancer is 
heterogeneous and can be classified into biologically meaningful and clinically 
meaningful subgroups (Weigelt et al., 2010). For clinical classification, breast 
cancer can be broadly classified into two types: in situ non-invasive cancer and 
invasive breast cancer. Non-invasive in situ breast cancer is comprised of ductal 
carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), which account for 
about 83% and 12% of all in situ cases respectively (The National Cancer 
Institutes SEER database from 2004 to 2010). Most in situ non-invasive breast 
cancers typically recur within 5 to 10 years. In the clinic, invasive breast cancers 
are staged based on the TNM staging system (T for primary tumors remaining 
within the breast, N for tumors infiltrating to the regional lymph nodes, M for 
presence or absence of distal metastases) according to the AJCC (American Joint 
Committee on Cancer) Cancer Staging Manual and Handbook. Cancers are 
further assigned a stage from 0 to IV (stage 0 reflecting in situ lesions, while 
stages I to III referring to invasive cancers in nearby lymph nodes and/or tissues; 
stage IV refers to metastatic cancer). The SEER Summary Stage system 
classifies patients into three groups; local stage that corresponds to stage I and 
partially stage II in the TNM staging system, regional stage that corresponds to 
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stage II or III, and distal stage that corresponds to stage IIIc and IV. The 5-year 
survival of patients diagnosed with localized or regional tumors (stage I-III) is 88% 
whereas only 22% of patients who develop tumors in distant organs survive 
greater than 5 years (The National Cancer Institutes SEER database of 2015) 
(Fig. 1.3). 
 
Figure 1.2 Breast tissue depicting normal or abnormal ducts and lobules 
Figure was adapted from Breast cancer information provided by American cancer 
society and was further modified. A woman’s normal breast mainly comprises 
lobules and ducts. The spaces between the lobules and ducts are filled with 
fibrous tissue and fat stroma. Most breast cancers originate from the abnormal 

















Figure 1.3 Breast cancer survival rates by stage 
The rates above come from the National Cancer Institutes SEER database of 
2015. The 5-year observed survival rate means the percentage of patients who 
live greater than or equal to 5 years after being diagnosed with breast cancer. 
Localized cancer refers to the cancer that is confined to primary site and regional 
cancer refers to the cancer that is spread to regional lymph nodes. Metastatic 
cancer refers to the cancer spread to distal organs. (stage 0 in situ lesions; stages 
I to III invasive cancers in nearby lymph nodes and/or tissues; stage IV metastatic 
cancer) 
In addition to the TNM staging system, during laboratory examination of 
breast cancer tissue, pathologists preferentially use a tumor grading system. 
Tumor grade indicates how abnormal the tumor tissue look under a microscope, 
which is an indicator of how quickly a tumor is likely to grow and spread (AJCC 
Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010). Grade 1 
corresponds to well-differentiated tumors displaying morphology similar to normal 
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cells. Grade 2 refers to moderately-differentiated tumors. Grade 3 refers to poorly 
differentiated tumors showing enhanced growth and invasiveness. Generally, 
higher tumor grade correlates with higher stage, and indicates a poorer prognosis. 
Breast cancers can be grouped into molecular subtypes which is 
associated with clinical outcomes. The major molecular subtypes of breast cancer 
are basal-like, luminal A, luminal B, HER2 positive/ER negative, and normal 
breast-like (Carey et al., 2006). It is possible that normal breast-like breast cancer 
could be falsely diagnosed as an artifact of sample presentation (contamination 
by high content of normal tissue) (Fig. 1.4). Currently there are two widely 
accepted hypothetical models explaining the origins of cancer; the cancer stem 
cell hypothesis and the clonal evolution model (Polyak, 2007). In the cancer stem 
cell theory, self-renewing, stem-like cancer cells exist and only this cancer stem 
cell population can drive cancer progression by accumulating genetic changes 
that are required for this process. In the clonal evolution theory, cross-talk among 
tumor-initiating cells and tumor stromal cells drives cancer progression and all 
tumor cells are capable of self-renewing division. The two models do not have to 
be mutually exclusive and a model encompassing clonal evolution of cancer stem 






Figure 1.4 Microarray-based breast cancer subtypes with 
immunohistochemical profile 
The hierarchical clustering analysis of intrinsic gene list with 
immunohistochemical classification schema is shown. The gene expression data 
for estrogen receptor (ER), human epidermal growth factor receptor-2 (HER2), 
CK5 (cytokeratin), and HER1 were obtained from the 115 patients’ tumor samples 
from the Carolina Breast Cancer Study (ascertained between May 1993 and 
December 1996). This figure was adapted from (Carey et al., 2006) and 
reproduced. 
Current therapies for breast cancer include surgery, radiation therapy, and 
systemic therapy including chemotherapy, hormone therapy, and targeted therapy 
(American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: 
American Cancer Society, Inc. 2013). In recent years, major accomplishments in 
drug development have resulted in the approval of drugs targeting hormone 
receptors highly expressed in breast cancer cells such as estrogen receptor (ER) 
Luminal A Luminal B
HER2+
/ ER- Basal-like Normal Breast-like
Microarray-based

















and progesterone receptor (PR) or targeting a growth-promoting protein, the 
erb-b2 receptor tyrosine kinase 2 (ERBB2, also known as HER2). Tamoxifen 
inhibits binding of estrogen to estrogen receptors. Trastuzumab (Herceptin), 
pertuzumab, ado-trastuzumb emtansine (adcyla, also known as TDM-1), and 
Lapatinib (Tykerb) function as inhibitors of HER2, resulting in reduced tumor size 
or repressed tumor growth. Treatment of ER positive, PR positive, or HER2 
positive breast cancer with these targeted therapies has contributed to improved 
survival. However, about 14 to 20% of all breast cancers are classified as Triple 
Negative Breast Cancer (TNBC) and do not overexpress HER2 or ER and PR. 
TNBC exhibits the worst outcome of the all breast cancer subtypes because these 
tumors tend to grow aggressively and are not susceptible to hormone therapy and 
anti-HER2 therapies (Koboldt et al., 2012). Considering that the majority of breast 
cancers with mutations in BRCA1 and BRCA2 have been classified as TNBC, the 
potential benefit of Poly (ADP-ribose) polymerase (PARP) inhibitors such as 
olaparib have been investigated as agents against BRCA1/BRCA2 mutant TNBC 
(Turner and Reis-Filho, 2006; Atchley et al., 2008). However, the biology of TNBC 
is poorly understood and targeted therapies for TNBC have not been approved.  
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PART II: METASTASIS 
 
Cancer is the second most common cause of death in the US, accounting 
for nearly 1 of every 4 deaths (American Cancer Society. Cancer Facts & Figures 
2014. Atlanta: American Cancer Society; 2014). The main cause of death in most 
cancer patients is metastasis, the spread of cancer cells from a primary tumor to 
distal organs (Batistatou et al., 2009). Therefore, understanding the biology of 
metastasis and developing therapies targeting this lethal process of cancer 
progression is crucial to reducing patient deaths. Metastasis has been viewed as 
a collective process consisting of sequential steps. After the transformation of 
normal cells to malignant cells, metastasis follows sequential steps such as the 
formation of blood vessels feeding nutrients to cancer cells and providing a route 
to distant organs, intravasation (invasion of cancer cells into the circulation), 
survival in circulation, extravasation (invasion of cancer cells out of vessel and 
into distal organ parenchyma), metastatic colony formation by proliferating cancer 
cells in end organs, growth, and re-initiation of these processes at secondary sites 
for metastasis to additional organs (Fig. 1.5). Given the complexities of the 
metastatic cascade, it is unlikely that a single gene would be sufficient to complete 
all steps in the metastatic cascade. 
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Figure 1.5 The sequential process of metastasis 
After the transformation of normal cells to malignant cells, metastatic progression 
follows sequential steps such as angiogenesis, intravasation, survival in 
circulation, extravasation, colony formation in secondary organs, and re-initiation 
of these processes at secondary sites for metastasis to additional organs. 
To understand this complex process of metastasis, I.J. Fidler and 
colleagues pioneered in vivo selection, a technique whereby sub-populations of 
tumor cells were selected for enhanced metastatic potential from the original 
non-metastatic tumor cell population (Fidler, 1973). It has been shown that 
primary tumors are genomically unstable with mutations in oncogenes and tumor 
suppressors and also exhibit epigenetic alterations. It also has been observed 
that the cell population in the primary tumor is heterogeneous and its 
subpopulations that endure selection pressures are capable of metastasis 
(Talmadge and Fidler, 1982; Nicolson and Dulski, 1986; Fidler, 2003). By 









parental breast cancer cells with highly metastatic sublines, we can identify the 
genes that are responsible for governing metastatic progression. 
From studies in various types of cancers, it has been suggested that tumor 
cells have preferences for certain sites of metastasis (Chambers et al., 2002). In 
breast cancer, liver, brain, bone, and lung have been reported as common 
secondary sites of breast cancer metastasis (Paget, 1989; Yoneda et al., 2001; 
Kang et al., 2003; Minn et al., 2005) whereas prostate cancer usually 
disseminates to bone, and colorectal cancer to liver (Rinker-Schaeffer et al., 2000; 
Kuo et al., 1995). This organ specificity hypothesis has been called the “seed and 
soil theory” of cancer spread — the site of secondary tumors is dependent on the 
origin of the tumor cell (“seed”) and the target organ (“soil”) — originally outlined 
by Stephen Paget in 1889. In support of this hypothesis, it has been observed that 
endothelial cells in vessels in different organs express different adhesion proteins 
that could affect patterns of metastatic tumor spread (Nicolson, 1988; Pauli et al., 
1990). Chemokines are also known to have a role in guiding organ specific 
metastasis. High levels of CXCL12, a soluble ligand for chemokine receptor 
CXCR4, in lung would guide breast cancer cells expressing high levels of CXCR4 
through chemokine-mediated signal pathways, which would result in metastatic 
colonization by breast cancer cells in lung (Mukherjee and Zhao, 2013). Similarly, 
melanoma cells express elevated levels of CCR10 receptor which would strongly 
bind to its ligand CCL27 that is highly expressed in skin, thereby contributing to 
melanoma metastasis to distant skin (Monteagudo et al., 2011). 
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MicroRNAs (miRNAs) are 19 to 24 nucleotides-long single-stranded RNA 
molecules that regulate gene expression in a sequence-specific manner. In the 
nucleus, RNA polymerase II transcribes a much longer pri-miRNA, which forms a 
hairpin loop structure. Then, Drosha cleaves the large pri-miRNA to generate the 
pre-miRNA that is then translocated to the cytoplasm by exportin 5-mediated 
export. In the cytoplasm, Dicer processes it into a short RNA duplex. This duplex 
is unwound upon loading into the RISC complex (RNA-induced silencing complex, 
comprising proteins such as Dicer and members of the Argonaute family) and 
finally the single-stranded mature miRNA is generated. Consequently, the mature 
miRNA is able to bind mRNAs through its seed sequence that are partially 
complementary to its target mRNA sequences. Thus target mRNAs could be 
degraded and translation could be suppressed through miRNA binding, which 
ultimately leads to a reduction in protein expression levels (Nicoloso et al., 2009). 
Considering that deregulated miRNAs could initiate alterations in expression of 
many downstream target genes, miRNAs are attractive candidates for clinical 
biomarker (Bartel, 2004; Zhang et al., 2007; Ventura and Jacks, 2009). 
Recently, in vivo selected cell lines have been used to identify molecular 
factors and key regulatory pathways that mediate metastasis in various cancer 
types (Minn et al., 2005; Gupta et al., 2005; Acharyya et al., 2012; Pencheva et 
al., 2012; Png et al., 2012; Loo et al., 2015). In breast cancer, molecular analysis 
of independently derived in vivo selected cell populations led to the identification 
of endogenous human microRNAs, miR-335 and miR-126, (miRNAs) that 
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suppress breast cancer metastasis (Tavazoie et al., 2008). These miRNAs are 
silenced in metastatic human breast cancer cell lines and restoring their 
expression in these cells dramatically suppresses lung and bone metastasis by 
breast cancer cells in mice. Supporting a clinical role for these miRNAs, reduced 
expression of miR-335 or miR-126 in human primary tumors is significantly 
associated with poor metastasis-free survival. 
Recent studies revealed that the activities of miRNAs demonstrate tissue 
specificity and can regulate different pathways during metastasis in different types 
of tissues. MiR-206 and miR-1 has been shown to negatively regulate 
angiogenesis during zebrafish development by targeting Vascular endothelial 
growth factor A (VegfA) in muscle (Stahlhut et al., 2012). Gastric cancer cells 
having downregulated expression of miR-206 displayed enhanced cells growth 
and colony forming ability (Zhang et al., 2013b). Recently it also has been 
reported that miR-206 loss also promotes gastric cancer metastasis by activating 
paired box gene 3 (PAX3) and MET proto-oncogene (MET) pathways (Zhang et 
al., 2015). In breast cancer, lower expression levels of miR-206 are correlated 
with larger tumor size whereas overexpression of miR-206 resulted in reduced cell 
proliferation by targeting cyclinD2 (Zhou et al., 2013). Molecular mechanism of 
miR-206 has been further studied in triple-negative breast cancer cells; miR-206 
repressed migration ability of triple-negative breast cancer cells by targeting 
actin-binding protein coronin 1C (CORO1C), resulting in changes in actin skeleton 
and cell morphology (Wang et al., 2014a). 
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Our laboratory has discovered the role of miR-126 in breast cancer 
metastasis (Png et al., 2012). By integrative transcriptomic profiling of highly lung 
metastatic compared to nonmetastatic breast cancer cells in the context of 
miR-126 overexpression and knockdown, Insulin-like growth factor binding protein 
2 (IGFBP2), phosphatidylinositol transfer protein (PITPNC1), and c-Mer tyrosine 
kinase (MERTK), were identified as miR-126 target genes that promote 
endothelial cell recruitment; IGFBP2 recruits endothelial cells to cancer cells 
through IGF1/IGF1R pathways. PITPNC1 promotes secretion of IGFBP2 by 
cancer cells. MERTK in cancer cells competes with MERTK in endothelial cells for 
binding to its ligand, growth arrest-specific 6 (GAS6), thereby resulting in 
promoting IGFBP2 independent endothelial cell recruitment. MiR-126 and 
miR-126* (a miRNA pair derived from a same precursor) has been also reported 
to suppress breast cancer metastasis by inhibiting mesenchymal stem cells and 
inflammatory monocytes (Zhang et al., 2013c). MiR-126 functions as metastasis 
suppressor in other types of cancer including hepatocellular carcinoma by 
targeting LRP6 and PIK3R2 to repress angiogenesis (Chen et al., 2013; Du et al., 
2014), colorectal cancer by repressing angiogenesis through inhibiting VEGF and 
by suppressing cell invasion via inactivation of RhoA/ROCK signaling pathway 




Similar to miR-206 and miR-126, miR-335 has also been reported as a 
metastasis suppressor in various types of cancer. MiR-335 suppresses ovarian 
cancer by repressing expression of B-cell CLL/lymphoma 2 like 2 (Bcl-w) and its 
effecter molecule matrix metalloproteinase-2 (MMP-2) (Cao et al., 2013). In 
osteosarcoma, downregulated miR-335 has been shown to be correlated with 
lymph node positive metastasis and it inhibits the cell migration and invasion by 
repressing Rho-associated coiled-coil containing protein kinase 1 (ROCK1) 
(Wang et al., 2013). It is known that miR-335 negatively regulates 
octamer-binding transcription factor 4 (OCT4) expression to suppress pancreatic 
cancer progression (Gao et al., 2014). Loss of miR-335 expression in breast 
cancer led to the enhanced expression of tenascin C (TNC) and the transcription 
factor SRY (sex determining region Y)-box 4 (SOX4), yielding enhanced 
metastatic progression through increased cell invasion and migration (Tavazoie et 
al., 2008). Along with the discovery of miR-335’s downstream target genes in 
breast cancer, our laboratory has also found that miR-335 expression is regulated 
in human breast cancer cells by genetic deletion and epigenetic silencing of the 
locus (Png et al., 2011). MiR-335 is located on human chromosome 7q32 domain, 
within the second intron of a paternally expressed gene, Mesoderm-specific 
transcript (MEST). Firstly, the expression of miR-335 and MEST have been found 
to be positively correlated in a number of cell lines. Additionally, the promoter 
region of MEST is highly methylated in metastatic breast cancer cells compared to 
poorly metastatic cells. Taken together, it is suggested that the low expression of 
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miR-335 in highly metastatic cells results from epigenetic silencing through 
hypermethylation of the promoter of MEST. Secondly, the miR-335 locus is 
deleted in highly metastatic derivatives compared to poorly metastatic parental 
cells. Thirdly, in the matched primary/metastasis clinical breast cancer patients 
samples, miR-335 expression in primary samples were higher than its expression 
in metastasis samples in which the reduction in miR-335 copy number were 
observed. 
Identification of master metastasis-regulating molecules like miRNAs is 
important because not only do these molecules provide clues about the 
downstream pathways involved in metastasis but they also could be attractive 
targets for more effective drug development. In line with this, global transcriptomic 
analysis following recent advances in sequencing technologies and computational 
biology has identified several transcription factors as regulators of metastasis. For 
example, a basic leucine zipper transcription factor, BACH1, has been identified 
as a key regulator of breast cancer bone metastasis by regulating MMP1 and 
CXCR4, both of which are known to promote metastasis by various types of 
tumors (Liang et al., 2012). A basic helix-loop-helix leucine-zipper transcription 
factor, C-Myc, has also been shown to function as oncogenic transcription factor 
which regulates invasion and migration by activating genes in the 
epithelial-mesenchymal transition (EMT) pathway like osteopontin and RhoA 
(Wolfer and Ramaswamy, 2011). Transforming growth factor β (TGFβ) mediated 
activation of mutant p53 pathway is also known to promote invasion and 
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metastasis by blocking p63, another transcription factor that suppresses 
metastasis (Clohessy and Pandolfi, 2009). Discovery of transcription factors 
functioning as positive or negative regulators of metastasis has raised interest in 
the development of drugs targeting such transcription factors and their 
downstream effectors (Ell and Kang, 2013).  
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PART III: ROLE OF SOX4 IN METASTASIS 
 
To date, 20 Sry-related HMG box (Sox) genes have been identified in 
vertebrate species, and are subdivided into 8 groups (A-H) based on sequence 
similarity of the HMG domain, full-length protein structure, and gene organization 
data (Bowles et al., 2000). Sox transcription factors are widely expressed in 
various tissues during early development. Since it was discovered as a master 
regulator of testis differentiation and expressed at the onset of gender 
determination (Eggers et al., 2014), Sox genes have been mostly studied in 
developmental biology. The group C of Sox transcription factors in most 
vertebrates consists of SOX4, SOX11, and SOX12. SoxC members have been 
shown to exhibit overlapping expression patterns and biological properties (Dy et 
al., 2008). They are highly co-expressed in neuronal and mesenchymal tissues in 
the developing mouse but also display independent expression patterns in various 
tissues. Sox11-deficient mice die at birth due to congenital cyanosis caused by 
heart defects (Sock et al., 2004). Sox11 depletion in sensory neurons results in 
reduction in neuronal survival and an arrest of axonal outgrowth (Lin et al., 
2010b). Sox12-deficient mice develop normally due to compensation of its loss by 




The human SOX4 gene was firstly characterized and mapped in 1993 (Farr 
et al., 1993) and its role as a transcription factor was first studied in mouse 
lymphocyte development (Vandewetering et al., 1993). It is known that the 
WWCAAG motif, a known functional T cell specific enhancer motif, is bound by 
DNA-binding HMG box proteins, T cell specific transcription factor 1 (TCF1) and 
lymphoid enhancer binding factor LEF1. It was observed that another HMG 
domain containing transcription factor family, the Sox transcription factors, were 
expressed in T and pre-B lymphocyte lines and in the murine thymus and could 
possibly bind the WWCAAG motif. The search for Sox genes that are responsible 
for transcriptional transactivation through the T cell specific enhancer motif 
revealed that SOX4 functions as a transcriptional activator in B lymphocyte 
differentiation. Hematopoietic cells with SOX4 deletion remained at the pro-B cell 
stage and the expression of SOX4 has been correlated with poor clinical outcome 
in B-cell leukemia. More recent studies have supported SOX4’s oncogenic role in 
leukemia in cooperation with other proteins such as SPI1 (ETS transcription factor 
family involved in hematopoietic development), CREB (a nuclear transcription 
factor critical for hemopoiesis), PML-RARα (a fusion product serving as the 
initiating event in acute promyelocytic leukemia), FRA-2 (an AP-1 transcription 
factor family member), and PI3K/AKT signaling molecules (Aue et al., 2011; 
Sandoval et al., 2012; Omidvar et al., 2013; Zhang et al., 2013a; Higuchi et al., 
2013; Ramezani-Rad et al., 2013). 
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In addition to the role of SOX4 in B cell differentiation, genetic inactivation 
of SOX4 in mouse revealed its critical role during heart development. Mammalian 
heart development requires coordinated regulation of cell differentiation at the 
correct time and migration into the correct place (Fig. 1.6 A). It begins with the 
formation of two endocardial tubes, which become a single primitive heart tube 
that eventually loops and septates into 4 chambers and arterial trunks. The 
truncus arteriosus should be further separated to become the two main arteries, 
the aorta and the pulmonary artery. The failure of the division of truncus arteriosus 
results in a phenotype called common arterial trunk with lack of ventricles 
(Buckingham et al., 2005) (Fig. 1.6 B). SOX4 null mice die from failure in 
circulation caused by severely impaired heart development at embryonic day (ED) 
14 (Schilham et al., 1996). The homozygous SOX4 deficient embryos were not 
distinguishable externally until the onset of valvular morphogenesis in the arterial 
pole of the heart, which happens between ED 12 and ED 13 (Ya et al., 1998). The 
outflow tract malfunction eventually results in edema which leads to embryonic 
lethality at ED 14. Histological evaluation of the SOX4 knockout embryo further 
demonstrated the common arterial trunk, which could result from impaired growth 
of the aorticopulmonary septum and the endocardial ridges of the outflow tract. 
Hypoplastic endocardial cushions and semilunar valves led incomplete ventricular 
septation and caused arterial blood back flow. 
 21 
 
Figure 1.6 Heart development 
(A) The embryological development of the human heart during the first 8 weeks is 
delineated. Heart originates from a pair of strands called cardiogeneic cords and 
endocardial tubes. The fusion of the strands then occurs and it starts 
differentiating into the truncus arteriosus, bulbus cordis, primitive ventricle, 
primitive atrium, and sinus venosus. This primitive heart forms an S shape, which 
determines the location of the chambers and major vessels of the adult heart. 
Illustration from Anatomy & Physiology, Connexions Web site. 
http://cnx.org/content/col11496/1.6/ (B) Common atrial trunk (Truncus arteriosus). 
Illustration from http://pixgood.com/persistent-truncus-arteriosus.html 
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In addition to its role in heart development, SOX4 is also known to regulate 
osteogenesis and insulin producing pancreatic cell development. SOX4 
heterozygous mice show defects in bone formation from an early age resulting 
from suppressed proliferation, differentiation, and mineralization of osteoblasts 
(Nissen-Meyer et al., 2007). SOX4 null pancreatic explants displayed reduced 
numbers of insulin producing beta cells (Maria E Wilson, 2005). 
Interestingly, as discussed earlier, the identification of SOX4 as a target of 
miR-335 shed light on the biological role of SOX4 in cancer. Silencing of miR-335 
in breast cancer cells results in the increased expression of tenascin C (TNC) and 
SOX4, enhanced cell invasion, migration, and metastatic progression. One of the 
miR-335 regulated genes, TNC, has been shown to support the 
metastasis-initiating capacity of breast cancer cells by enhancing the expression 
of musashi homolog 1 (MSI1) and leucine-rich repeat-containing G 
protein-coupuled receptor 5 (LGR5), a positive regulator of NOTCH signaling and 
a target gene of the WNT pathway, respectively (Oskarsson et al., 2011). The 
other miR-335 regulated gene, SOX4, has been shown to play important roles in 
cancer progression and metastasis. Subsequent to its discovery as a mediator of 
breast cancer metastasis, more recent studies have shown that SOX4 expression 
is elevated in other cancer types, including leukemia (Zhang et al., 2013a; 
Ramezani-Rad et al., 2013), glioblastoma (Ikushima et al., 2009; Lin et al., 
2010a), medulloblastoma (Lee et al., 2002; de Bont et al., 2008), hepatocellular 
carcinoma (HCC) (Liao et al., 2008), and prostate cancer (Liu et al., 2006; Scharer 
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et al., 2009; Lai et al., 2011). 
Despite the above evidence supporting the oncogenic properties of SOX4, 
the SOX4 regulatory program appears to be cell type and context specific 
(Vervoort et al., 2013b). SOX4 regulatory networks found in prostate cancer 
include transducin-like enhance of split (TLE-1), BCL2 binding component 3 
(BBC3/PUMA), and epidermal growth factor receptor (EGFR) (Liu et al., 2006; 
Scharer et al., 2009; Lai et al., 2011). In HCC, two genes in the category of axon 
guidance, neurophilin-1 (NRP1) and semaphorin 3C (SEMA3C), were identified 
as SOX4 target genes that promote migration and intrahepatic metastasis of HCC 
cell (Liao et al., 2008). In glioblastoma, TGF-β-mediated SOX4 induction 
promotes the expression of Sox2 to maintain the stemness of glioma-initiating 
cells (Ikushima et al., 2009; Lin et al., 2010a). In leukemia, SOX4 has been shown 
to transcriptionally activate promoters of multiple components within the 
PI3K/AKT and MAPK signaling pathways (Zhang et al., 2013a; Ramezani-Rad et 
al., 2013). However, the question remains whether there exists SOX4 target 
genes that drive a common metastasis-related SOX4-dependent phenotypes 
such as invasion and migration in multiple cell types. In this study, we identify and 
characterize TMEM2 as a metastasis-promoting gene that is transcriptionally 
regulated by SOX4 in metastatic breast cancer cells and mediates pro-migratory 




SYSTEMATIC ANALYSIS OF SOX4-REGULATED TARGET GENES  
IN BREAST CANCER 
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PART I: TRANSCRIPTOMIC PROFILING 
To identify potential SOX4 target genes, we employed ChIP-Seq and 
transcriptomic profiling approaches. Given that SOX4 is a known transcriptional 
activator, and its expression is upregulated in highly metastatic LM2 cells 
compared to poorly metastatic MDA-MB-231 cells, we searched for genes for 
which expression levels were decreased following RNA interference-mediated 
SOX4 depletion, and that exhibited increased expression in the metastatic LM2 
cells, which endogenously express higher levels of SOX4 relative to their parental 
line. By comparing microarray expression profiles of LM2 cells transfected with 
either an siRNA targeting SOX4 or a control siRNA, we identified possible 
SOX4-regulated genes which expression was diminished in cells depleted of 
SOX4 relative to control cells. Biological replicates were used for this analysis. 
The cells were transfected using independent siRNAs, and RNA was extracted 96 
hours after siRNA transfection using the miRVana kit according to the 
manufacturer’s instructions. RNA samples were processed by the Genomics core 
facility at Rockefeller University using Illumina BeadChip arrays (HumanHT-12 V4 
BeadChip). RAW signals from each samples were median-normalized and the 
ratio between SOX4 knockdown and controls was calculated by averaging the 
normalized signal from the biological replicates. Of 31,424 genes tested, 2,225 
genes were down-regulated in the SOX4 knockdown cells compared to the control 
cells (genes that were expressed lower than SOX4). The relative expression 
levels of these 2,225 genes were determined from a microarray experiment 
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comparing MDA-MB-231 cells and LM2 cells. Of the 2,225 genes downregulated 
upon SOX4 depletion, 1,961 genes were upregulated in the LM2 relative to the 
MDA-MB-231. There were 1,961 genes whose expression fold enrichment in LM2 
relative to the MDA-MB-231 was equal or higher than the SOX4 fold enrichment. 
PART II: PREDICTION OF POTENTIAL SOX4-REGULATED DIRECT TARGET 
GENES BY CHIP-SEQ 
Summary 
To determine which of these genes might be direct transcriptional targets 
of SOX4, we performed chromatin immunoprecipitation of SOX4, followed by high 
throughput sequencing (ChIP-Seq) in LM2 cells. Considering that the C-terminal 
33 amino acids of SOX4 constitute the transactivation domain (Dy et al., 2008), 
we engineered LM2 cells to stably express exogenous N-terminal FLAG-tagged 
SOX4 to prevent interfere of the FLAG peptide with its transactivation activity. 
Additionally, we produced control cells, expressing an empty vector and used 
anti-FLAG antibodies for immunoprecipitation. Sequencing peaks from 
empty-vector expressing cells were used as the negative control to remove 
background reads caused by potential non-specific binding of the FLAG antibody 
to DNA. Analysis of peaks from SOX4 binding events in the LM2 cells revealed 
that the majority of SOX4-DNA interactions were in intergenic regions, followed by 
distal regions, introns, and promoter regions (Fig. 2.1 A). To identify SOX4 binding 
motifs in LM2 cells, the ChIP-Seq data was analyzed by FIRE (Finding Informative 
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Regulatory Elements), a motif discovery and characterization program based on 
mutual information (Elemento et al., 2007). FIRE analysis revealed that the DNA 
sequence SRAAATATCY was statistically over-represented in the ChIP-Seq 
peaks identified in the SOX4 overexpressing LM2 cells (Fig. 2.1 B). This A/T-rich 
motif is consistent with known SOX4 binding sites obtained from global analysis of 
the sequence-specific binding of human transcription factors using 





Figure 2.1 ChIP-Seq analysis of SOX4 in LM2 cells 
(A) Pie chart depicting the distribution of clustering of enriched DNA sequences 
obtained from N-terminal FLAG tagged SOX4 expressing LM2 cells. (B) The 
enriched SOX4 binding motifs from the true peak sequences identified by FIRE 
analysis. 
Although microarray technology has been widely used to screen target 
genes of transcription factors, it produces a large number of false positives. Also, 
it is impossible to distinguish a direct target from an indirect target by this 
approach. In the case of a direct target, a transcription factor binds directly to 













an indirect target, a transcription factor is still functionally responsible for 
regulating the downstream gene, but does not directly bind to the regulatory 
region of the gene. Instead, the transcription factor directly regulates the 
expression of an upstream regulatory protein that then directly controls the 
expression of the gene (Weinmann, 2004). To circumvent this, ChIP-Seq can be 
used to identify both direct targets and the binding motifs (Qin et al., 2011). SOX 
transcription factor family members all bind a similar DNA motif WWCAAW 
(Vandewetering et al., 1993) and various sequences for SOX4 binding sites have 
been reported in different types of cells. In human mammary epithelial cells, 
SOX4 was shown to bind an intronic region of CDH2, with the binding site 
sequence of either CCTTTGTT or AACAATGA (Vervoort et al., 2013a). In T 
helper type 2 cells, SOX4 binding sites are located near GATA-3 binding sites, 
and the sequence of the binding site is TGATTGTT (Kuwahara et al., 2012). In 
prostate cancer cells SOX4 was shown to bind the motif AACAAAGG (Scharer et 
al., 2009). Therefore we decided to use both SOX4 ChIP-Seq data and microarray 
gene expression data to discover direct targets of SOX4 and to identify SOX4 
binding motifs. 
Total cell lysate from LM2 cells that were transduced with either a control 
empty vector or a FLAG-SOX4 vector were immunoprecipitated with anti-FLAG 
beads and then immunoblotted with an anti-FLAG mouse monoclonal antibody 




Figure 2.2 Immunoprecipitation of FLAG-SOX4 for ChIP-Seq 
(A-B) Nuclear lysate from LM2 cells over-expressing either FLAG-SOX4 or control 
empty vector were immunoprecipitated with anti-FLAG beads, separated by 
SDS-PAGE and visualized by immunoblot with anti-FLAG antibody (A) and 
anti-SOX4 antibody (B). 
The ChIP-Seq data was analyzed by FIRE to find the SOX4 consensus 
binding motifs in this system. As a control, we used randomly generated 
sequences of identical length while keeping the di-nucleotide frequencies 
constant. Frequencies of each motif were compared to the frequency of random 
sequences. The likelihood of SOX4 binding to the sequences obtained from the 
ChIP-Seq experiment versus random sequences were measured using mutual 
information and the Z score was calculated from the mutual information obtained 
from 10,000 random shufflings of the motifs. FIRE analysis revealed that the DNA 
sequence SRAAATATCY was statistically over-represented in the SOX4 
ChIP-Seq data. This analysis of the ChIP-Seq data revealed that 426 genes were 
significantly bound by SOX4. The 1,961 genes that were downregulated in the 
context of SOX4 knockdown as well as upregulated in LM2 compared to 
Control + — + —
FLAG-SOX4 — + — +
anti-SOX4
Control + — + —
FLAG-SOX4 — + — +
anti-FLAG
Input FLAG-IPInput FLAG-IP BA
Control + — + —
FLAG-SOX4 — + — +
anti-SOX4
Control + — + —
FLAG-SOX4 — + — +
anti-FLAG
Input FLAG-IPInput FLAG-IP BA
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MDA-MB-231 cells, were then overlapped with the 426 genes that were bound by 
SOX4. From this analysis, we identified 6 genes that were putative direct SOX4 
target genes (Fig. 2.3 A-C). 
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Figure 2.3 A systematic strategy for identification of direct SOX4 target 
genes that regulate breast cancer metastasis  
(A) Potential functional SOX4 target genes were identified by the overlap between 
genes whose expression were depleted in the context of SOX4 knockdown by two 
independent siRNAs versus control siRNA (cut-off 1.2 fold-decrease), upregulated 
in metastatic breast cancer cell population LM2 relative to parental MDA-MB-231 
(cut-off 1.3 fold-increase), and genes whose promoter regions were identified to 
be bound by SOX4 through ChIP-Seq (𝑃 < 1×10!!). (B-C) Heat map depicting 
the mRNAs of putative SOX4 target genes. Red represents higher expression and 
blue lower expression levels. (B) Relative expression levels of the 6 genes from 
microarray data from LM2 cells expressing control siRNA or two independent 
siRNAs targeting SOX4. (C) Relative expression levels of the 6 genes from 
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CHAPTER 3 
VALIDATION OF MICROARRAY ANALYSIS 
 35 
PART I: QRT-PCR VALIDATION OF SOX4-REGULATED TARGET GENES 
 
To validate our gene expression profiling analyses, we performed 
quantitative real-time polymerase chain reaction (qRT-PCR) for these genes. By 
qRT-PCR, we observed that the mRNA levels of RPH3AL, SLC3A2, and TMEM2, 
three of the six potential targets of SOX4, were upregulated in the highly 
metastatic LM2 cells which endogenously overexpress SOX4 relative to the 
poorly metastatic MDA-MB-231 parental cell line (Fig. 3.1 D, E, G). Depletion of 
SOX4 by two independent siRNAs targeting SOX4 resulted in significant reduction 
of the RNA levels of RPH3AL, SLC3A2, and TMEM2 relative to the control siRNA 




Figure 3.1 QRT-PCR validation of the 5 putative SOX4 regulated target 
genes in MDA-MB-231/LM2 cell lines 
(A-G) qRT-PCR measurements of mRNA expression of 6 target genes in the 
parental MDA-MB-231 cells as well as LM2 cells (n=3). (H-N) qRT-PCR 
measurements of mRNA expression of 6 target genes in LM2 cells transfected 
with control siRNA or two siRNAs targeting SOX4 (n=3). 
The relative expression level of these three genes and SOX4 was further 
assessed in the CN34 cell line, an independent malignant breast cancer cell 
population, and its highly metastatic lung derivative, the LM1A subline. All three 
genes were upregulated in the LM1A subline which over expresses endogenous 
SOX4 relative to its non-metastatic CN34 parental line (Fig. 3.2 D, E, G). 
Knockdown of SOX4 in LM1A cells also decreased mRNA levels of the three 
genes (Fig. 3.2 K, L, N), suggesting that these genes could be SOX4-regulated 













































































































































































































































































































































































































































































































































































































Figure 3.2 QRT-PCR validation of the 3 putative SOX4 regulated target 
genes in CN34/LM1A cell lines 
(A-G) Relative expression of the 6 genes in the CN34 parental cells as well as 
LM1A cells (n=3). (H-N) Relative expression of the 6 genes in LM1A cells 













































































































































































































































































































































































































































































































































































































PART II: EVALUATION OF CLINICAL ASSOCIATION OF SOX4 AND TARGET 
GENES 
 
We then asked if SOX4 and its putative target genes, RPH3AL, SLC3A2, 
and TMEM2, might be clinically relevant in breast cancer progression. To test if 
there is any correlation between the expression of these genes and SOX4 in 
breast cancer, we next investigated the expression levels of these genes in 
transcriptomic profiling datasets comprised of non-cancerous and cancerous 
breast tissue. Oncomine Cancer Microarray database showed that SLC3A2 and 
TMEM2 were highly ranked by overexpression in cancerous tissues when SOX4 
was overexpressed (Fig. 3.3 A). Consistent with this, these two genes showed a 
statistically significant positive correlation with SOX4 in the Expression Project for 
Oncology (ExpO) microarray database (Fig. 3.3 B). 
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Figure 3.3 Clinical correlation with SOX4 and the 3 putative target genes in 
breast cancer 
(A) mRNA expression levels of SOX4 and its 3 putative target genes in either 
breast carcinoma or normal tissue obtained from Oncomine Cancer Microarray 
database. The rank for a gene is the median rank for that gene across each of the 
analyses. The p-value for a gene is its p-value for the median-ranked analysis. (B) 
The expression correlation of SOX4 with SLC3A2 or TMEM2 analyzed in the 
ExpO breast cancer database (www.intgen.org), which consists of a total of 243 
tumors from 4 patients in stage 0, 38 patients in stage 1, 129 patients in stage 2, 
67 patients in stage 3, and 5 patients in stage 4. Bonferroni correction was used to 
adjust confidence intervals (critical p value < 0.007). 
ExpO data set (243 tumors)
Pearson correlation 
coefficient p-value critical p-value  < 0.007
SLC3A2 0.212176086 0.0009 *
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Since SOX4 is a transcriptional activator, and a validated promoter of 
cancer progression, we focused on SLC3A2 and TMEM2, the genes that were 
positively correlated with SOX4 expression. Next, we wondered whether SOX4 
was sufficient to increase mRNA levels of both genes. MDA-MB-231 cells 
expressing stable FLAG-SOX4 showed increased mRNA levels of SLC3A2 and 
TMEM2 relative to the control empty vector expressing cells (Fig. 3.4 A-C). As an 
independent method, we generated doxycycline inducible FLAG-SOX4 
expressing MDA-MB-231 and CN34 cell lines. Interestingly in both cell lines, 
TMEM2 mRNA levels were increased 24 hours post doxycycline treatment 
whereas SLC3A2 mRNA levels were increased after 36 hours post doxycycline 
treatment (Fig. 3.4 D-I). The degree of increase was also different. The induction 
of TMEM2 mRNA levels (Fig. 3.4 F, I) was stronger than that of SLC3A2 (Fig. 3.4 
E, H) by doxycycline inducible FLAG-SOX4 expression in both cell lines. These 
results suggest there may be differential sensitivity of target genes to SOX4. 
Additionally, SLC3A2 might have an indirect component to its up regulation that 




Figure 3.4 Induction of SLC3A2 and TMEM2 transcript levels by SOX4 
overexpression in breast cancer cell lines 
(A-C) Assessment of mRNA levels for SOX4, SLC3A2 and TMEM2 in the control 
or FLAG-SOX4 overexpressing MDA-MB-231 cells (n=2). (D-F) Assessment of 
mRNA levels for SOX4, SLC3A2 and TMEM2 in Doxycycline inducible 
FLAG-SOX4 overexpressing MDA-MB-231 cells (n=2). (G-I) Assessment of 
mRNA levels for SOX4, SLC3A2 and TMEM2 in Doxycycline inducible 
FLAG-SOX4 overexpressing CN34 cells (n=2). 


















































































































































































To evaluate prognostic value of SLC3A2 and TMEM2, we examined the 
transcript levels of SOX4 and the target genes in a cohort of tissues of grade 3 
from breast cancer patients. Patients with grade 3 breast tumors with higher 
SOX4 expression levels trended towards having shorter overall survival times 
relative to patients with grade 3 breast tumors with lower SOX4 expression. 
Interestingly, patients with higher levels of TMEM2 had significantly shorter overall 
survival times relative to patients with lower levels of TMEM2 (Fig. 3.5 A). 
Moreover, high expression of both SOX4 and TMEM2 most significantly 
correlated with poor overall survival times (Fig. 3.5 B). Consistent with this, 
TMEM2 was positively correlated with SOX4 in The Cancer Genome Atlas 
(TCGA) data set for invasive breast carcinoma (Fig. 3.5 C). In addition, patients 
assigned to higher stage (stage III or IV) showed 2.5 fold stronger positive 
correlation relative to lower stage (stage I or II) (Fig. 3.5 D-E). SLC3A2 did not 
show correlation in this patient data set.
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Figure 3.5 Clinical relevance of TMEM2 in patients with aggressive breast 
tumors  
(A-B) Kaplan-Meier overall survival curves demonstrating patients diagnosed with 
grade 3 tumors (N=262) expressing higher levels of TMEM2 (A) and both SOX4 
and TMEM2 (B) to have poorer survival than those with grade 3 tumors 
expressing lower levels. p=0.03393 and 0.00484 respectively. Each color 
represents patients whose tumors’ expression levels for each gene were higher 
(red) or lower (grey) than the median (yellow). (C-E) Clinical correlation of TMEM2 
and SOX4 expression in TCGA breast cancer patient data set. SOX4 expression 
level is displayed on x-axis and TMEM2 on y-axis. Each data points represents 
individual breast cancer patients assigned from stage I to IV (C), stage I to II (D), 
or stage III to IV (E). TCGA Breast Invasive Carcinoma data were obtained 
through the cBioPortal for Cancer Genomics (www.cbioportal.org) and UCSC 
cancer browser (genome-cancer.ucsc.edu). 
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Clinical relevance of TMEM2 in breast cancer patients with grade 3 tumors 
and sensitive induction of mRNA levels by SOX4 overexpression suggest TMEM2 
as a functional direct target of SOX4. We next wondered if mRNA levels of 
TMEM2 are also dependent on SOX4 in lung cancer, a cancer in which SOX4 has 
been reported to be overexpressed (Medina et al., 2009; Castillo et al., 2012). We 
depleted SOX4 in the A549 and H522 cell lines, derived from non-small cell lung 
cancer (NSCLC), which accounts for 85-90% of lung cancers (Haghgoo et al., 
2015). TMEM2 transcripts were significantly downregulated upon SOX4 depletion 
in both cell lines, which is consistent with our observations in breast cancer cell 
lines (Fig. 3.6 A-D). Given that the A549 and H522 NSCLC cell lines tested in our 
study showed the expression of TMEM2 is dependent on SOX4 by RNAi, we 
wondered if TMEM2 is also clinically relevant in NSCLC. We used online survival 
analysis software (Gyorffy et al., 2010) to assess the prognostic value of TMEM2. 
Interestingly, high expression of TMEM2 was associated with shorter overall 
survival times in patients with lung adenocarcinoma, a NSCLC subtype that 
accounts for approximately 40% of NSCLC (American Cancer Society. Cancer 




Figure 3.6 Clinical relevance of TMEM2 in patients with lung 
adenocarcinoma 
(A-B) Relative expression levels of SOX4 (A) and TMEM2 (B) in lung 
adenocarcinoma A549 cells with or without SOX4 knockdown (n=2). (C-D) SOX4 
(C) and TMEM2 (D) expression levels in SOX4 knockdown cells versus control in 
lung adenocarcinoma H522 cells (n=2). (E) Kaplan-Meier curves depicting overall 
survival time of patients having NSCLC adenocarcinoma histologic types (n=719) 
as a function of TMEM2 expression levels in tumors. The hazard ratio with 95% 
confidence intervals and log-rank P value for the two patient cohorts were 
calculated by Kaplan-Meier plotter (www.kmplot.com). 
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Given the lack of treatment for late stage breast cancer patients, the 
synergistic outcome of SOX4/TMEM2 in predicting survival of patients with 
advanced stage tumors is attractive. Additionally, as an extracellular 
transmembrane protein, TMEM2 could have advantages as a target for drug 
development since major accomplishments in drug discovery have resulted in the 
development of drugs targeting membrane-bound proteins like Tamoxifen and 
Herceptin. Therefore understanding the cell biological mechanism by which 
TMEM2 regulates metastatic progression could provide better therapeutic 
intervention for patients suffering from the most aggressive tumors. 
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PART III: TRANSCRIPTIONAL REGULATION OF TMEM2 BY SOX4 
We next investigated whether TMEM2 is transcriptionally regulated by 
SOX4. The binding of SOX4 in the TMEM2 promoter was tested by CHIP-qPCR 
(Fig. 3.7 A). QPCR detection of distinct genomic regions of TMEM2 in 
immunoprecipitated DNA pulled down by a SOX4 antibody in metastatic LM2 cells 
revealed that a region spanning from -856 bp to -1178 bp was highly enriched 
relative to IgG control immunoprecipitated DNA (Fig. 3.7 B). We next asked which 
DNA sequences were sufficient to promote SOX4-dependent transcriptional 
induction of TMEM2. To do this, we used luciferase promoter assays. A reporter 
construct consisting of a luciferase reporter under the regulation of TMEM2 
promoter regions were generated. Exogenously overexpressed SOX4 increased 
luciferase activity relative to control, consistent with a SOX4-dependent increase 
in transcription from the TMEM2 promoter (Fig. 3.7 C). In order to further identify 
the SOX4 binding motifs in this region, we searched for occurrences of the SOX4 
binding motif in this region, cloned each of the three motifs found, and tested them 
in luciferase promoter reporter assays. The SOX4 high mobility group (HMG) box, 
a protein domain that mediates DNA binding, has been shown to preferentially 
bind the AACAAAG motif in electrophoretic mobility shift assays (EMSA) 
(Vandewetering et al., 1993) and TATTGTC and CATTGTG in promoter reporter 
constructs (Bergsland et al., 2006; Dy et al., 2008). In the context of SOX4 
overexpression, TMEM2 promoter regions containing SOX4 motifs drove 
luciferase expression (Fig. 3.7 D). Among the three putative SOX4 binding sites, 
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the highest luciferase activity was driven by the B2 motif (TACAAAG), which is the 
closest motif to the known SOX4 binding motif (AACAAAG). 
Given that pre-mRNAs are transient intermediates and their steady-state 
amount at any given time reflects endogenous transcription prior to nuclear 
processing (Lipson and Baserga, 1989; Luco and Misteli, 2011; de Almeida and 
Carmo-Fonseca, 2012; Montes et al., 2012; Shukla and Oberdoerffer, 2012), we 
analyzed the levels of intron-containing TMEM2 pre-mRNA precursors in control 
and SOX4 depleted cells by qRT-PCR. SOX4 knockdown caused a significant 
reduction of TMEM2 pre-mRNA levels relative to control cells (Fig. 3.7 E-F). 
These collective findings support a model whereby SOX4 transcriptionally 
regulates TMEM2 expression.
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Figure 3.7 Identification of TMEM2 as a SOX4-regulated direct target gene 
(A) ChIP-qPCR assessment with primers detecting different regions of TMEM2 
promoter. Sheared DNA from LM2 cells fixed with 1% paraformaldehyde was 
immunoprecipitated with anti-SOX4 antibody or control IgG. (B) Schematic 
depicting promoter region of TMEM2 amplified by each qPCR primers used in (A). 
TMEM2 promoter region detected by qPCR primer #3 and #4 have three putative 
SOX4 binding motifs marked by B1, B2, and B3. (C) Functional validation of the 
ChIP-qPCR by luciferase reporter assay. TMEM2 promoter region containing all 
three putative SOX4 binding motifs were cloned upstream of a luciferase reporter. 
A relative luciferase activity of this region was increased by SOX4 overexpression 
relative to the control (n=3). (D) Identification of functional SOX4 binding motif in 
TMEM2 promoter region tested in (C) by luciferase reporter assays. Putative 
SOX4 binding motifs, B1, B2, and B3, were individually cloned upstream of a 
luciferase reporter and its effect on luciferase expression by SOX4 
overexpression was measured. (E-F) pre-mRNA levels of TMEM2 in the LM2 
cells expressing either siRNAs targeting SOX4 or a control siRNA were assessed 























































































































































PART IV: IN VITRO AND IN VIVO FUNCTIONAL VALIDATION OF 
SOX4-REGULATED DIRECT TARGET GENE, TMEM2 
TMEM2-mediated effects of SOX4 on cell invasion and migration 
Highly metastatic LM2 cells express higher levels of SOX4 relative to 
MDA-MB-231 cells, and the capacity of LM2 cells to invade through matrigel and 
to metastasize to the lungs in vivo was reduced upon SOX4 knockdown (Tavazoie 
et al., 2008). To determine if increased SOX4 expression is sufficient to enhance 
invasive capacity, we overexpressed SOX4 in two independent breast cancer cell 
lines, MDA-MB-231 and CN34, both of which express lower levels of SOX4 
relative to their highly metastatic sub-lines, and performed matrigel invasion 
assays. Exogenous SOX4 overexpression increased matrigel invasion capacity 
by more than 50% in both cell lines (Fig. 3.8 A-B). In SOX4 overexpressing 
MDA-MB-231 cells, TMEM2 was transcriptionally induced by 1.5 fold relative to 
control cells expressing empty vector (Fig. 3.4 A, C). We next investigated 
whether the enhanced cell invasion caused by SOX4 overexpressing 
MDA-MB-231 cells was mediated by TMEM2. Indeed, knockdown of TMEM2 in 
SOX4 overexpressing cells significantly reduced (50%) the enhanced capacity of 
cells to invade through matrigel (Fig. 3.8 C). Consistent with this, transient 
overexpression of SOX4 in CN34 cells increased cellular matrigel invasion, an 
effect that was abrogated upon TMEM2 depletion (Fig. 3.8 D-F). This suggests 
that the increased invasion conferred by SOX4 overexpression is dependent, at 
least in part, on its downstream target gene, TMEM2. Similarly, significantly 
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greater invasion and migration capacity was observed in MDA-MB-231 cells 
overexpressing TMEM2 relative to control cells (Fig. 3.8 G-H), and the converse 
effect was observed in LM2 cells upon TMEM2 depletion (Fig. 3.8 I-J). These 
findings are consistent with a model whereby the pro-invasive effects of SOX4 are 
mediated, at least in part, through the transcriptional induction of TMEM2.
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Figure 3.8 TMEM2 mediates the effects of SOX4 on cell invasion and 
migration 
(A-B) Matrigel invasion by 5 × 104 MDA-MB-231 cells expressing either a control 
vector or FLAG-SOX4 (A, n=6) and by 1 × 105 CN34 cells expressing either 
control or FLAG-SOX4 (B, n=5). Images of DAPI stained cells were obtained at 
10× magnifications and quantified by Image J. (C) Matrigel invasion by 
MDA-MB-231 cells after knockdown of TMEM2 in the context of constitutive 
expression of FLAG-SOX4 (n=4-5). (D) Matrigel invasion by knockdown of 
TMEM2 in the context of doxycycline inducible FLAG-SOX4 overexpression in 
CN34 cells (n=3-4). (E-F) Expression of SOX4 (E) and TMEM2 (F) in CN34 cells 
expressing doxycycline inducible FLAG-SOX4 48hours after doxycycline 
induction (n=2). (G) Enhanced matrigel invasion by MDA-MB-231 cells 
overexpressing TMEM2 compared to the control cells (n=4). (H) Increased 
trans-well migration by MDA-MB-231 cells overexpressing TMEM2 compared to 
the control cells (n=4). (I-J) Reduced matrigel invasion (I) and trans-well migration 
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Promotion of in vivo metastasis by TMEM2 
Based on our molecular and in vitro findings, we predicted that TMEM2 
could have an impact on metastasis, similar to the one we observed by SOX4 
(Tavazoie et al., 2008). The role of TMEM2 in metastatic colonization was tested 
by carrying out loss-of-function and gain-of-function studies. Depleting TMEM2 in 
highly metastatic LM2 cells strongly reduced metastatic colonization (Fig. 3.9 A-B) 
whereas TMEM2 over-expression significantly enhanced the metastatic capacity 
(Fig. 3.9 C-D). These in vivo metastatic phenotypes mirror the effects of SOX4 on 
metastasis and suggest that SOX4 mediates its effects on metastasis, at least in 




Figure 3.9 TMEM2 promotes in vivo metastatic lung colonization 
(A) Bioluminescence imaging plot of lung metastasis by 4 × 104 LM2 cells 
expressing control shRNA or shRNA targeting TMEM2 (n=5). NOD-SCID gamma 
female mice were imaged every seven days and bioluminescence signals were 
normalized to the signal on day 0. (B) Knockdown efficiency of TMEM2 measured 
by qRT-PCR in LM2 cells injected into the tail-vein of mice. (C-D) 
Bioluminescence imaging plot of lung metastasis by LM2 cells expressing control 
or TMEM2 (C, n=5) and mRNA levels of TMEM2 measured by qRT-PCR in LM2 
cells injected into the tail-vein of NOD-SCID gamma female mice (D). 






















































































































By using an unbiased, genomic and molecular approach, we have 
identified TMEM2 as a direct transcriptional target of SOX4 in multiple cancer 
types. We find that SOX4 directly binds to the TMEM2 promoter and 
transcriptionally activates it in a sequence-specific manner. Molecular studies 
reveal that SOX4 regulates endogenous TMEM2 pre-mRNA levels—consistent 
with a transcriptional regulatory role. TMEM2 promotes cancer cell migration, 
invasion, and metastatic colonization—phenocopying SOX4-dependent effects. 
Moreover, we find that TMEM2—a gene that has not been previously implicated in 
cancer progression—positively associates with breast cancer and lung cancer 
clinical progression. 
The role of SOX4 in cancer progression 
SOX4 was originally identified as a transcriptional activator in B and T 
lymphocytes (Schilham et al., 1996). Consistent with its expression in 
lymphocytes during development, SOX4 deficiency was found to result in 
abnormal thymocyte differentiation (Schilham et al., 1997). Further 
characterization showed that SOX4 belongs to the HMG box superfamily of 
DNA-binding proteins and contains a single HMG domain that allows it to bind 
DNA in a sequence specific manner (Vandewetering et al., 1993; Bergsland et al., 
2006; Dy et al., 2008; Jolma et al., 2013). In addition to its role in lymphocytes, 
genetic studies in knockout mice revealed that SOX4 is required for normal 
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cardiac development. Loss of SOX4 activity was found to result in impaired 
maturation of endocardial ridges into semilunar valves as well as the ventricular 
septum outlet (Schilham et al., 1996; Ya et al., 1998; Buckingham et al., 2005). 
This phenotype mirrored what is seen in humans as the ‘common arterial trunk’ 
phenotype. SOX4 was subsequently found to be over-expressed in various 
cancers (Frierson et al., 2002; Sinner et al., 2007; Huang et al., 2012) and 
amplified in lung cancer (Medina et al., 2009). 
The identification of metastasis suppressor miRNAs in breast cancer led to 
the identification of a cancer progression role for SOX4—as a driver of cancer cell 
invasion and migration. SOX4 was found to be targeted by the metastasis 
suppressor miRNA miR-335. As a result of miR-335 silencing in metastatic breast 
cancer, SOX4 expression is enhanced (Tavazoie et al., 2008). The enhancement 
of invasive and migratory phenotypes by SOX4 resulted in augmented metastatic 
lung colonization capacity of breast cancer cells. A number of additional studies 
have revealed that SOX4 can promote cancer progression in a number of 
additional cancer types such as prostate cancer (Liu et al., 2006; Scharer et al., 
2009; Lai et al., 2011), hepatocellular carcinoma (Liao et al., 2008), glioblastoma 
(Ikushima et al., 2009; Lin et al., 2010a), and leukemia (Zhang et al., 2013a; 
Ramezani-Rad et al., 2013). Although SOX4 has been found to promote cancer 
cell migration and invasion in multiple cancer types, direct target(s) of SOX4 that 




TMEM2 is a poorly described transmembrane protein. It was identified to 
be associated with autosomal recessive non-syndromic hearing loss. However, 
no genetic mutations in TMEM2 have been identified that associate with hearing 
loss. A type II transmembrane protein, TMEM2 is composed of a N-terminal 
transmembrane domain, a G8 domain and a GG domain. Both G8 and GG 
domains are within extracellular sequences. The G8 domain is named for its eight 
conserved glycine residues, which may be important for correct folding of the 
β-strand/helix structure (He et al., 2006; Guo et al., 2006). The GG domain 
consists of two conserved glycines. To date, no biochemical functions have been 
identified for these domains (Guo et al., 2006) (Fig. 4.1 A). The structure of 
TMEM2 is highly conserved in vertebrates. 
Recent studies have revealed a role for TMEM2 in heart development of 
zebrafish (Smith et al., 2011; Totong et al., 2011). Two independent groups have 
identified two zebrafish mutants, named wickham (wkm) and frozen ventricle (frv). 
Wkm displayed a specific loss of cardiac looping at later developmental stages 
and frv exhibited aberrant atrioventricular canal differentiation. Both mutations 
occur in the TMEM2 locus. Wild type TMEM2 has 1378 amino acids whereas the 
frv mutant expresses a truncated (Fig. 4.1 B-C). TMEM2 that does not have 
amino acids from 876 to the end results in a shortened extracellular domain. The 
above study suggests that a part of the missing extracellular domain is important 
for its function during cardiac development. These two groups have also shown 
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that TMEM2 can function in the endocardium to suppress atrioventricular 
differentiation within the ventricle by inhibiting bone morphogenetic protein 4 
(Bmp4). During cardiac development, BMP2 and BMP4 are involved in the 
lengthening of the outflow tract, proper positioning of the outflow vessels, and 
septation of the atria, ventricle and atrioventricular canal (Goldman et al., 2009). 
The phenotype resulting from loss of BMP2 and BMP4 signaling resembles the 
common arterial trunk phenotype of the SOX4 null mouse. In the myocardium, 
TMEM2 promotes the migration of myocardial and endocardial cells. It is 
interesting that TMEM2 functions in heart development in part by regulating cell 
migration, which resembles the role of SOX4 in both mouse heart development 
and breast cancer metastasis. 
 
Figure 4.1 Graphical view of domain structure of TMEM2 




























Given the above evidences that all three genes have roles in heart 
development, and that SOX4 is implicated in cancer metastasis, it is possible that 
the SOX4, BMP2/4 and TMEM2 axis could represent a common pathway that is 
important in both heart development and cancer progression. Interestingly, in the 
context of cancer, recent studies have revealed that SOX4 and Bmp4 have 
important roles in glioblastoma; Ikushima et al. showed that TGFβ activates 
SOX4, which then leads to elevated SOX2 expression, which is responsible for 
maintaining the glioma-initiating stem cell population (Ikushima et al., 2009). 
Piccirillo et al. showed that another member of the TGFβ family, Bmp4, reduced 
the glioma-initiating stem cell population (Piccirillo et al., 2006). In breast cancer, 
SOX4 was previously shown to directly regulate an EMT regulator, EZH2, in a 
TGFβ-dependent manner (Ikushima et al., 2009) and Bmp4 has been reported to 
inhibit metastasis by blocking myeloid-derived suppressor cell activity (Cao et al., 
2014). Based on the above evidences, SOX4, TMEM2, and members of the BMP 
family could play dual roles in cardiac development and metastasis. 
From the results presented in the current thesis, TMEM2 could possibly 
regulate cell migration and invasion by engaging with BMP signaling pathways. It 
would be interesting to investigate if TMEM2 could interact with either the 
extracellular signaling ligands BMP or BMP-specific transmembrane receptors 
expressed in breast cancer cells in a positive feedback regulation of the pathway. 
Alternatively and equally interesting, would be to determine the molecular 
mechanism by which TMEM2 induces cell migration and invasion phenotypes. 
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This could be performed through co-immunoprecipitation experiments and mass 
spectrometry to identify interacting partners of TMEM2. 
While we have identified TMEM2 as one transcriptional target of SOX4 
(Fig. 4.2), our findings do not exclude the likely possibility that there exist 
additional direct transcriptional targets that mediate the SOX4-dependent 
pro-invasive and pro-migratory effects. One open question is what are the 
co-factors required for the transcriptional activation of TMEM2? Are those 
co-factors predictors of metastasis and what is their tissue specificity? 
Additionally, it will be important to study the transcriptional landscape of SOX4 
during development in specific tissues such as the heart and lymphocytes in order 
to establish the breadth of its transcriptional program during development and try 
to understand the mechanisms by which cancer cells appropriate those 




Figure 4.2 A SOX4 transcriptional network that regulates breast cancer 
metastasis through transcriptional activation of TMEM2 
TMEM2 was identified as a gene that regulates myocardial and 
endocardial morphogenesis and its genetic inactivation was found to result in 
abnormal cardiac development. While the relationship between SOX4 and 
TMEM2 was previously unknown, the regulation of TMEM2 by SOX4 in cancer 
cells, the similarity of the SOX4 and TMEM2 phenotypes in cancer, and the 
common phenotypes resulting from the genetic inactivation of these genes, 
suggest that SOX4 and TMEM2 may form a pathway that governs normal 
cardiovascular development. Future studies are needed to determine if SOX4 
regulates TMEM2 expression in the developing heart and, if so, whether enforced 












N6-METHYLADENOSINE MARKS PRIMARY MICRORNAS FOR PROCESSING 
Claudio R. Alarcón, Hyeseung Lee, Hani Goodarzi, Nils Halberg and 
Sohail F. Tavazoie, Nature, 2015 
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PART I: DISCOVERY OF THE ROLE OF METHYLTRANSFERASE-LIKE 3 
(METTL3) IN MICRORNA PROCESSING 
Summary 
The first step in the biogenesis of miRNAs is the processing of primary 
miRNAs (pri-miRNAs) by the microprocessor complex, composed of the RNA 
binding protein DGCR8 and the ribonuclease type III DROSHA (Denli et al., 2004; 
Gregory et al., 2004; Han et al., 2004; Landthaler et al., 2004). This initial event 
requires the recognition of the junction between the stem and the flanking 
single-stranded RNA of the pri-miRNA hairpin by DGCR8 followed by recruitment 
of DROSHA, which cleaves the RNA duplex to yield the pre-miRNA product (Han 
et al., 2006). While the mechanisms underlying pri-miRNA processing have been 
elucidated, the mechanism by which DGCR8 recognizes and binds pri-miRNAs as 
opposed to other secondary structures present in transcripts is not understood. 
We find that methyltransferase like 3 (METTL3) methylates pri-miRNAs, 
marking them for recognition and processing by DGCR8. Consistent with this, 
METTL3 depletion reduced the binding of DGCR8 to pri-miRNAs and resulted in 
the global reduction of mature miRNAs and concomitant accumulation of 
unprocessed pri-miRNAs. In vitro processing reactions confirmed the sufficiency 
of the m6A mark in promoting pri-miRNA processing. 
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Finally, gain-of-function experiments revealed that METTL3 is sufficient to 
enhance miRNA maturation in a global and non-cell-type-specific manner. Our 
findings reveal that the m6A mark acts as a key post-transcriptional modification 
that drives the initiation of miRNA biogenesis. 
Identification of the METTL3 recognition motif, GGAC, in pri-miRNA 
sequences 
In our search for post-transcriptional modifications that regulate miRNA 
processing, we conducted a systematic search for sequence motifs that are 
over-represented in miRNA-containing regions using the FIRE algorithm, a 
well-established computational framework for the unbiased identification of 
cis-regulatory elements present in primary sequences (Elemento et al., 2007). We 
observed the over-representation of the GGAC motif in pri-miRNA sequences 
relative to shuffled sequences (Fig. 5.1 A). This motif is consistent with a 
previously established recognition sequence ([GAU][GAU]AC) for the RNA 
methyltransferase enzyme METTL3 (Wei and Moss, 1977; Dominissini et al., 
2012; Meyer et al., 2012). In contrast to pri-miRNA sequences, this element was 
not enriched in pre-miRNA sequences, and was actually depleted relative to 
shuffled sequences (Fig. 5.1 B). METTL3 is the catalytic subunit of a 
multi-component enzyme that methylates RNA, thereby adding the 
N6-methyladenosine (m6A) mark to eukaryotic RNAs (Bokar et al., 1997; Sibbritt 
et al., 2013). The biological function of the m6A modification in eukaryotes has 
just recently begun to be investigated, and includes RNA splicing (Dominissini et 
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al., 2012), mRNA stability (Wang et al., 2014b; c), and circadian clock speed 
control (Fustin et al., 2013). 
To determine if the over-representation of the m6A methylation motif in 
pri-miRNA sequences signifies increased m6A methylated sequences, we 
conducted m6A-seq (Dominissini et al., 2012), by immunoprecipitating nuclear 
RNA from the MDA-MB-231 breast cancer cell line with an anti-m6A antibody 
followed by RNA seq (Fig. 5.1 C). An unbiased search for cis-regulatory elements 
from m6A-seq revealed a significant enrichment of the METTL3 motif relative to 
shuffled sequences (Fig. 5.1 D). Furthermore, when we analyzed the density of 
the peaks in the vicinity of miRNA loci, we found a substantial increase in the 
density of peaks proximal to pre-miRNA sequences, corresponding to pri-miRNA 
regions (Fig. 5.1 E). We next inspected individual clusters of reads using the 
Integrative Genomics Viewer (IGV) software (Thorvaldsdottir et al., 2013) and 
found numerous cases in which there were significant peaks in locations that 
correspond to pri-miRNAs. These clusters were located in both intergenic and 
intragenic pri-miRNA sites that contained canonical METTL3 motifs (Fig. 5.1 F). 
Thus, these results reveal that the m6A modification is enriched within pri-miRNA 
sequences.
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Figure 5.1 m6A mark is present in pri-miRNAs regions  
(A) Motif discovery analysis in pri-miRNA sequences using FIRE, reveals 
over-representation of the METTL3 motif, where yellow represents 
over-representation and blue under-representation. The magnitude of the 
over/under-representation is reflected in the linear scale heat-map shown at the 
bottom. The z-score is specified on the right. (B) Unbiased search for 
cis-regulatory elements using the FIRE algorithm. FIRE motif discovery analysis 
of pre-miRNAs and pri-miRNA sequences as well as random sequences of the 
same length reveals over-representation of the METTL3 motif in pri-miRNAs 
sequences but not in pre-miRNAs. Yellow represents over-representation, and 
blue under-representation. The magnitude of the over/under-representation is 
represented by the linear scale heat-map on the left. A schematic representation 
of a pre and a pri-miRNA is shown on the right. (C) Schematic representation of 
the m6A-seq protocol. (D) FIRE analysis of the m6A peaks compared to controls 
sequences of the same length. The over-represented motif and their z-score are 
depicted on the right as in (A). (E) Density plot of the abundance of the m6A 
marks and their proximity to miRNA within transcripts. Peaks obtained from the 
IgG immunoprecipitation were used as controls. (F-I) IGV tracks displaying 
examples of sequencing read clusters from two m6A-seq replicates are shown 
next to the pre-miRNA genomic loci. The green dots at the bottom of the tracks 
depict the position of METTL3 consensus motifs. The upper most tracks at the top 
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Role of METTL3 in pri-miRNA processing 
To determine if METTL3 plays a role in miRNA processing, we conducted 
genome-wide miRNA expression profiling of MDA-MB-231 cells expressing a 
control shRNA as well as MDA-MB-231 cells expressing two independent 
shRNAs targeting METTL3 (Fig. 5.2 A-B). METTL3 depletion using independent 
shRNAs led to a global downregulation of mature miRNAs (p=2.15 × 10-15; Fig. 
5.2 C-D). Remarkably, most miRNAs (~70%) were downregulated by at least 
30%. The miRNAs affected by METTL3 depletion were diverse in terms of their 
genomic locations, with the most abundant being intronic (56%), followed by 
intergenic (29%), exonic (12%) and finally those located in untranslated regions 
(UTRs; 3%), indicating that the effect of METTL3 depletion on miRNA processing 
was not specific to miRNAs originating from specific locations within or outside of 
genes (Fig. 5.2 E)
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Figure 5.2 METTL3 modulates the expression levels of miRNAs 
(A-B) qRT-PCR (A) and western blot (B) quantifications of METTL3 depletion 
upon transduction with two independent shRNAs against METTL3 (METTL3 KD1 
and METTL3 KD2) in MDA-MB-231 cells. Samples were normalized to GAPDH. 
The data from biological triplicates is shown. Bar graphs represent a linear scale 
and error bars represent s.d. ***, p-value <0.0005. (C) Histogram depicting fold 
change (log2) in miRNA expression, as obtained by genome-wide miRNA 
expression profiling, of MDA-MB-231 cells expressing two independent shRNAs 
targeting METTL3 compared to two samples expressing control shRNAs. The 
ratio of the average of the two independent shRNAs over the average of the two 
controls is shown. The p-value of the analysis is indicated. (D) A volcano plot 
representation of the microarray of miRNAs shown in (C), where the y-axis 
represents the -log10 of the p-value, and the x-axis represents the fold change 
(log2) between the expression levels of the miRNA from the METTL3 depletion 
(average of two independent shRNAs) versus the average of two control samples. 
(E) Pie-chart representation of the genomic locations of miRNAs downregulated 








































































We next validated specific miRNAs by qRT-PCR (Fig. 5.3). Importantly, the 
effect of METTL3 depletion on miRNA processing was not restricted to a 
particular cell line and was also observed in HeLa cells and primary human 
umbilical vein endothelial cells (Fig. 5.4). These experiments demonstrate that 
METTL3 is required for the basal expression of the vast majority of miRNAs in 




Figure 5.3 Mature miRNAs are downregulated upon METTL3 depletion in 
MDA-MB-231 cells 
(A) Heat-map representation of the quantification by qRT-PCR of eight 
representative mature miRNAs that were affected by METTL3 depletion. Red 
represents increased expression while blue represents reduced expression. At 
the bottom, a heat map depicts their aggregate expression upon METTL3 
modulation. (B) Quantification of representative miRNAs that were affected by 
METTL3 depletion in MDA-MB-231 cells as measured by qRT-PCR. Samples 
were normalized to SNORD44 (RNU44). (C) An example of a small RNA that did 
not display expression level changes upon METTL3 knockdown 
(SNORD44, small nucleolar RNA) normalized to 18S. All the experiments were 
done in biological replicates. Bar graphs represent a linear scale and error bars 
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Figure 5.4 Mature miRNAs are downregulated upon METTL3 depletion in 
multiple mammalian cell lines 
(A) qRT-PCR quantification of examples of miRNAs that were modulated by 
METTL3 depletion in HeLa cells. Samples were normalized to RNU44. (B) 
Expression levels of genes used for normalization. All experiments were done in 
biological replicates. (C-D) qRT-PCR (C) and western blot (D) quantifications of 
METTL3 depletion upon transduction with two independent shRNAs targeting 
METTL3. (E) Expression levels of representative miRNAs that were affected by 
METTL3 depletion in HUVEC cells, as measured by qRT-PCR. Normalization of 
the samples was obtained using RNU44 as endogenous control. (F) qRT-PCR 
quantification of METTL3 depletion upon transduction with two independent 
shRNAs against METTL3. (G) Quantification of the expression levels of control 
genes. (H-I) Examples of miRNAs affected in mouse embryonic stem cells in 
which Mettl3 has been targeted using CRISPR, whose expression levels were 
measured by qRT-PCR. All experiments were done in biological replicates. Bar 
graphs represent a linear scale and error bars represent s.d. **** 𝑃 < 1×10!!, *** 
































































































































































































































To test if METTL3 expression is sufficient to promote miRNA processing, 
we stably overexpressed METTL3 in MDA-MB-231 cells. METTL3 overexpression 
was sufficient to significantly increase the expression levels of mature miRNAs 
(Fig. 5.5). We then quantified the expression levels of pri-miRNAs to determine if 
METTL3 depletion could impact pri-miRNA levels. As expected, we observed a 
clear and significant up-regulation in the levels of pri-miRNAs upon METTL3 
depletion (Fig. 5.6 A-C). These effects required enzymatically active METTL3 
since they were abrogated upon mutation of the predicted catalytic residues 
(Bujnicki et al., 2002) (Fig. 5.6 D-E). Neither METTL3 depletion nor its 
overexpression altered the expression, sub-cellular localization, or activity of the 
Microprocessor—consistent with a direct role of METTL3 in pri-miRNA processing 
(Fig. 5.7). Our findings reveal that pri-miRNAs are marked by the METTL3 m6A 
modification and that METTL3 expression is required for the appropriate 
processing of most pri-miRNAs to mature miRNAs. 
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Figure 5.5 Mature miRNAs are upregulated by METTL3 over-expression in 
MDA-MB-231 cells 
(A) Heat-map representation of the quantification of mature miRNAs from (Figure 
5.3 A) by qRT-PCR upon METTL3 over-expression (B) qRT-PCR quantification of 
representative miRNAs that were modulated upon METTL3 over-expression 
(METTL3 OE) in MDA-MB-231 cells. Samples were normalized to RNU44. (C) 
qRT-PCR quantification of control RNU44 and GAPDH genes normalized to 18S. 
All experiments were done in biological replicates. Bar graphs represent a linear 
scale and error bars represent s.d. **** 𝑃 < 1×10!!, *** 𝑃 < 5×10!!, ** 
















































































































Figure 5.6 Quantification of pri-miRNAs levels upon depletion and catalytic 
inactivation of METTL3 in MDA-MB-231 cells 
(A) Heat-map representing the quantification of pri-miRNA forms of miRNAs from 
Fig. 5.3 (A) and Fig. 5.5 (A) by qRT-PCR upon METTL3 depletion. (B) qRT-PCR 
quantification of representative pri-miRNAs that were impacted by METTL3 
depletion using two independent hairpins in MDA-MB-231 cells. Expression levels 
were normalized to GAPDH. (C) qRT-PCR quantification of GAPDH, endogenous 
control. All experiments were done in biological replicates. (D-E) Quantification of 
mature (D) and pri-miRNAs (E) when MDA-MB-231 cells were stably transduced 
with either wildtype or a catalytic mutant METTL3. Mature miRNA expression was 
normalized by RNU44 and pri-miRNAs by GAPDH expression levels. The last bar 
graph shows the average of all the individual miRNA tested. The experiments 
were done in biological replicates. Bar graphs represent a linear scale and error 
bars represent s.d. **** 𝑃 < 1×10!!, *** 𝑃 < 5×10!!, ** 𝑃 < 1×10!!, * 
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Figure 5.7 Expression and localization of the Microprocessor under 
depletion and overexpression of METTL3 
(A) Western blot analysis of METTL3, DROSHA and DGCR8 obtained from 
nuclear and cytoplasmic fractions of cells transduced with two independent 
shRNAs against METTL3 (shMETTL3 #1 and #2) or with an shRNA control (shC). 
Tubulin and Histone 3 were used as loading controls as well as controls for the 
efficiency of the fractionation. (B) Same as (A), but in this case lysate from cells 
overexpressing METTL3 were compared to wildtype control cells. (C) In vitro 
pri-miRNA processing reactions. Whole cell extracts of control cells or cells 
depleted of METTL3 with 2 independent shRNAs were used to process in vitro 
transcribed pri-miR-1-1 to produce pre-miR-1-1 in vitro. Pre-miR-1-1 levels were 
then analyzed by Northern blot. (D) Hybridization intensities of (C) were 
quantified, normalized by their inputs and shown in a bar graph format. Bar 
graphs represent a linear scale and error bars represent s.d. 
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METTL3 marks pri-miRNAs 
In order to directly implicate METTL3 in the m6A methylation of 
pri-miRNAs, we conducted high-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation (HITS-CLIP) (Chi et al., 2009) experiments 
using an antibody against endogenous METTL3 in HeLa cells, and an anti-Flag 
antibody in MDA-MB-231 cells overexpressing Flag-epitope tagged METTL3 (Fig. 
5.8 A-B). We next performed an unbiased search for cis-regulatory elements in 
the METTL3 HITS-CLIP reads to further validate that the sequences obtained 
from HITS-CLIP contained the METTL3 signature. Consistent with our findings 
from m6A-seq, METTL3-HITS-CLIP sequences displayed a significant enrichment 
of the METTL3 motif (Fig. 5.8 C). Despite the transient nature of the interaction 
between METTL3 and its targets, we observed a significant overlap in the 
miRNAs affected by METTL3 depletion that shared both the METTL3 footprint by 
HITS-CLIP and the m6A mark by m6A-seq (𝑃 = 2.4×10!!"; Fig. 5.8 D-E). 
In order to investigate the evolutionary conservation of the METTL3 motif 
across different species, we used the PhastCons software (Pollard et al., 2010) to 
analyze 30 miRNAs that are conserved among 100 vertebrates (targetscan.org) 
and also contain m6A and/or METTL3 tags. This analysis showed a high degree 
of conservation for the METTL3 motif among vertebrates (Fig. 5.8 F). These 
highly conserved regions were located next to the pre-miRNA regions but also 
hundreds of base pairs away from mature miRNA loci, as shown in the examples 
aligned using UCSC Genome Browser (Kent et al., 2002) (Fig. 5.8 G).  
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Figure 5.8 METTL3 targets pri-miRNAs for m6A methylation 
(A) Schematic representation of the HITS-CLIP protocol used. (B) IGV tracks 
displaying sequencing read clusters from two independent HITS-CLIP 
experiments, one surveying endogenous METTL3 binding sites in HeLa cells 
(dark blue) and the other surveying Flag-METTL3 binding sites in MDA-MB-231 
cells (light blue). The experiments were done in biological triplicates; the reads 
next to the miR-663b locus are shown as an example. (C) FIRE analysis provides 
motif of METTL3 HITS-CLIP binding sites. The color scale of the linear scale heat 
map is the same as in Fig. 5.1 A. (D) An example of sequencing clusters obtained 
from METTL3 HITS-CLIP (blue) and m6A-seq (red). m6A seq was done in 
duplicate using IgG as control. METTL3 HITS-CLIP was done in triplicate. The 
purple boxes at the bottom of the tracks represent conserved METTL3 motifs. (E) 
Venn diagram representation of the overlap of the miRNAs affected by METTL3 
depletion and bearing the m6A and/or the METTL3 HITS-CLIP tags within 1kb 
from any particular miRNA locus. The overlap of miRNAs containing both m6A 
and METTL3 HITS-CLIP tags is depicted in red, 𝑃 = 2.4×10!!". (F) Average 
conservation of the METTL3 motif among vertebrates using the PhastCons 
software. Error bars represent s.d. (G) Two examples of pri-miRNA genomic 
regions containing METTL3 clusters obtained from HITS-CLIP are shown. Partial 
pre-miRNA (filled red boxes) sequences are shown in the first example and 
METTL3 HITS-CLIP clusters are depicted in a blue box. The conserved METTL3 
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Role of the m6A modification by METTL3 in pri-miRNA processing 
To demonstrate a direct role of the m6A modification in pri-miRNA 
processing we performed in vitro processing reactions using whole cell extracts 
from HEK293T cells transfected with DGCR8 and DROSHA (Lee and Kim, 2007). 
In this gain-of-function experiment, the extracts were used to process in vitro 
transcribed pri-miRNAs containing modified N6-methyladenosine or unmodified 
bases. Consistent with our model, methylated pri-let-7e was more efficiently 
processed by the microprocessor to produce pre-let7e relative to its 
un-methylated counterpart as detected by northern blot. For a normalization 
control, we included in each reaction the un-methylated pri-miR-1-1 (Fig. 5.9 A-C). 
These in vitro experiments suggest that m6A marks in pri-miRNAs are required for 
efficient processing of pri-miRNAs in vitro. Additionally, we performed a 
loss-of-function experiment by testing the impact on miRNA processing of 
mutating select adenosines present in potential METTL3 motifs located in a 
pri-miRNA. To do this, we modified a previously described reporter construct 
(Auyeung et al., 2013). In one reporter, we introduced a wild type version of 
pri-let-7e, while in the other, the adenosines of the METTL3 motifs present in the 
pri-let-7e region (i.e. 5 out of 18 adenosines present outside the pre-miRNA 
sequence) were mutated (Fig. 5.9 D). Each reporter contained an internal control 
miRNA, pri-miR-1-1, which is co-transcribed and used for let-7e expression 
normalization. This control miRNA was also mutated in both vectors to make its 
processing independent of methylation. These reporters were transfected into 
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HEK293T cells and RNA was extracted to analyze the expression levels of mature 
let-7e and mature miR-1-1. Consistent with our findings, mutation of METTL3 
motifs in pri-let-7e significantly reduced its processing to the mature form (Fig. 5.9 
E). 
Since the m6A mark is added to the pri-miRNA, and we observed an 
accumulation of unprocessed pri-miRNAs upon METTL3 depletion, we 
questioned whether METTL3 is required for the engagement of the pri-miRNA by 
the microprocessor. We first tested whether METTL3 and DGCR8 are part of a 
complex. Immunoprecipitation of METTL3 from nuclear lysates co-precipitated 
DGCR8; however this interaction was mediated through RNA, since RNase 
treatment disrupted this association (Fig. 5.9 F). We next sought to determine 
whether DGCR8 interacts with methylated RNA in vivo. To do this, we 
UV-crosslinked cells, isolated nuclear fractions and immunoprecipitated 
endogenous DGCR8. After immunoprecipitation of DGCR8 and 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), m6A immunoblotting 
revealed that DGCR8 indeed interacts with methylated RNA (Fig. 5.9 G). Based 
on our observations, we predicted that a reduction in METTL3 levels should 
decrease the levels of methylated RNA bound by DGCR8. Indeed, depleting 
METTL3 significantly reduced the m6A methylated RNA bound by DGCR8 (Fig. 
5.9 H). However, the binding of DGCR8 to methylated RNA is unlikely to be direct, 
as we detected no preference for DGCR8 binding to methylated RNA over 
unmethylated RNA in vitro (Fig. 5.9 I). 
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Since mRNAs tend to form secondary structures including short hairpins 
that resemble pri-miRNAs, a potential basis of pri-miRNA methylation might be to 
confer specificity for, and facilitate the recognition of, pri-miRNA structures by 
DGCR8. Based on this hypothesis, we would expect that a reduction in the levels 
of methylated pri-miRNAs would reduce the total amount of RNA recognized and 
bound by DGCR8. To test this, we immunoprecipitated DGCR8 from control and 
METTL3 depleted cells and radio-labeled the total RNA bound to DGCR8. 
Consistent with our model, METTL3 depletion significantly reduced the amount of 
total RNA (Fig. 5.9 J) as well as pri-miRNAs (Fig. 5.10) bound by DGCR8. These 
findings suggest that the m6A methylation mark allows for the effective 
recognition of pri-miRNAs by DGCR8 and their subsequent processing to pre-and 
mature miRNAs. 
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Figure 5.9 m6A methylation of pri-miRNAs is required for normal 
processing by DGCR8 
(A) In vitro pri-miRNA processing reactions. Pri-let-7e, was transcribed with either 
a modified N6-methyladenosine (depicted in the schematic as red dots) or with 
unmodified bases, was co-incubated in the cell extract with pri-miR-1-1 and the 
production of pre-let-7e as well as pre-miR-1-1 was analyzed by northern blot. (B) 
Hybridization intensities were quantified and shown in the bar graph. Bars 
represent the average normalized intensity of three biological replicates, * 
𝑃 < 5×10!!. (C) Input for experiment shown in (A). (D-E) In vitro assays. (D) 
Schematic representation of the reporters used to study the role of the METTL3 
on the processing of pri-miRNAs. Represented in red is the pri-let-7e sequence 
and in green, the control pri-miR-1-1. The top reporter contains a wildtype 
sequence of the pri-let-7e and the potential sites of methylations are depicted as 
red dots. The reporter on the bottom contains a mutant version of pri-let-7e in 
which the 5 putative adenines of the METTL3 motif were mutated. (E) HEK293T 
cells were transfected with the reporters depicted in (D), RNA was extracted, and 
mature miRNA expression quantified by qRT-PCR. The bar graph represents the 
relative expression levels of mature let-7e normalized to mature miR-1-1. (F) 
Co-immunoprecipitation of the METTL3-interacting protein DGCR8. Western blot 
using the indicated antibodies with IgG used as control for the IP.  
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(G) Immunoprecipitation of endogenous DGCR8. Western blot using an antibody 
against m6A methylated RNA with IgG used as control for the IP. (H) Similar as 
(G), but control cells or cells depleted of METTL3 were compared. (I) In vitro 
binding assays using immunopurified DGCR8. Samples containing in vitro 
transcribed pri-let-7e with N6-methyladenosine or unmodified adenosines were 
incubated with magnetic beads bound-DGCR8, washed, eluted and analyzed by 
Northern blot. All reactions contained unmodified pri-miR-1-1 as endogenous 
control. The upper panel shows pri-let-7e and the lower panel pri-miR-1-1. On the 
right side the bar graph depict the average intensity of the pri-let-7e normalized by 
pri-miR-1-1 levels. The experiment was done in biological triplicate. Bar graphs 
represent a linear scale and error bars represent s.d., *** 𝑃 < 5×10!!, ns= not 
statistically significant. (J) Similar immunoprecipitation as (G), however, after 
immunoprecipitation of DGCR8, a radiolabelled RNA linker was ligated to the RNA 
bound by DGCR8. Bars represent the average normalized intensity of three 
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Figure 5.10 Effect of METTL3 depletion on endogenous pri-miRNAs binding 
to DGCR8 
(A) Immunoprecipitation of endogenous DGCR8 crosslinked to RNA of control 
cells or cells depleted of METTL3 using two independent shRNAs. After the 
immunoprecipitation the RNA was extracted and a panel of pri-miRNAs was 
quantified by qRT-PCR. (B) The average quantification of (A). Bar graphs 
represent a linear scale and error bars represent s.d., **** 𝑃 < 1×10!!, *** 




















































































PART II: DISCUSSION 
By using an unbiased approach, we have identified m6A as a novel 
regulator of miRNA processing. Our findings reveal that METTL3 methylates 
primary inter- and intragenic miRNAs. The m6A modification facilitates the 
recognition of pri-miRNA sequences and marks an initiation event in miRNA 
biogenesis (Fig. 5.11). We propose that the m6A mark on transcripts at pri-miRNA 
sequences initiates a global co-transcriptional program comprising the 
engagement and processing of primary miRNAs by the microprocessor 
machinery. The m6A mark thus plays an important role in the nucleus—allowing 
the microprocessor complex to recognize its intended substrates as opposed to 
potential hairpin structures not containing miRNA products. Additionally, altered 
METTL3 expression in various human malignancies may significantly contribute 
to the aberrant expression of miRNAs seen cancer. 
 
Figure 5.11 Model of METTL3 regulation of miRNA biogenesis 
The molecules represented in the schematic are: histones (yellow), RNA Pol II 
(orange), METTL3 (green), m6A (red), DGCR8 (blue), DROSHA (pink) and a 









The MDA-MB-231 line, its metastatic derivatives LM2 cells, CN34 parental cells, 
and its metastatic derivatives LM1A cells have been cultured as described 
previously (Minn et al., 2005). Briefly, all these four breast cancer cell lines, 
HEK293T, and HeLa cells were propagated in vitro with Dulbecco’s modified 
Eagles medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin-streptomycin, 2mM L-Glutamine, 1mM sodium pyruvate, and 2.5 ug/mL 
fungizone. The lung cancer cell line H522 was purchased from ATCC and the 
A549 cell line was a kind gift from H. Choi, a graduate student in Dr. V. MITTAL 
laboratory in Weill Cornell Medical College. Lung cancer cell lines were cultured in 
RPMI media with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, 2mM 
L-Glutamine, 1mM sodium pyruvate, 2.5 ug/mL fungizone, 1mM HEPES, and 
0.15% Sodium bicarbonate. HUVECs were cultured with Endothelial Cell Growth 
Media (CC-3162, Lonza). Experiments with HUVEC were conducted with cells 
from passage 2 to 5. 
Generation of lentivirus, retrovirus, knockdown and over-expressing cells 
Generation of lentivirus-mediated knockdown and retroviral-overexpressing cells 
were performed as described previously (Minn et al., 2005; Tavazoie et al., 2008). 
For overexpression studies, human cDNA of SOX4 with N-terminal FLAG tag was 
cloned into pBabe-puro retroviral expression vector. 10 ug of DNA were 
transfected into H29 packaging cell line in a 10cm plate by Lipofectamine 2000 
(ratio of ug DNA: uL Lipofectamine 2000 is 1:4). Virus-containing supernatant at 
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48hr and 72hr post-transfection were harvested, filtered through a 0.45 µm 
syringe filter, and added to the 70% confluent breast cancer cells in a 10cm plate 
with polybrene (8 ug/mL). After over-night incubation, cells were recovered with 
fresh growth media for 1 day and cultured with growth media containing 
puromycin (1 ug/mL) for 2-3 days. Human cDNA of TMEM2 with C-terminal V5 tag 
was obtained from CCSB Lentiviral Expression Library (OHS6087) (Yang et al., 
2011). The C-terminal frame shift mutation present in the ORFeome library was 
fixed and cloned into pLX304 lentiviral expression vector by Gateway cloning. For 
overexpression of METTL3, human cDNA of METTL3 with C-terminal FLAG tag 
was cloned into pBabe-Puro retroviral expression vector. Refer to list of cloning 
primers in Appendix. 
For knockdown studies, commercially available shRNA glycerol stocks were 
purchased (Sigma). Two shRNAs against SOX4 that showed best knockdown 
efficiency (TRCN0000018216, TRCN0000018217), two shRNAs against TMEM2 
(TRCN0000148114, TRCN0000147636), two shRNAs targeting METTL3 
(TRCN0000034715, TRCN0000034717) and control shRNA (SHC002) were used 
for experiments. 2.5 ug of pLKO lentiviral plasmid with lentiviral packaging 
plasmids (5 ug of gag/pol and 2.5 ug of env) was co-transfected into HEK293T 
cells in a 10cm plate by Lipofectamine 2000. Lentivirus-containing supernatant 
were harvested and processed in the same way as described above. 
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Generation of inducible over-expressing cells 
N-terminal FLAG tagged SOX4 was pcr amplified and sub-cloned into pEN_Tmcs 
Entry vector (Addgene Plasmid #25751) which has TRE promoter followed by 
multiple cloning sites. Then this entry vector was digested with BamHI and EcoRV 
to be ligated with pSLIK-Neo lentiviral vector (Addgene plasmid #25735) that was 
digested with AleI and XhoI. Since EcoRV and AleI generate blunt ends, the 
digested pSLIK-Neo lentiviral vector was CIP-treated and then both insert and the 
vector were blunt-ended by Klenow followed by ligation. Sequence verified 
construct was used to generate doxycycline inducible SOX4 expression cell lines. 
siRNA-mediated mRNA knockdown 
Cells were seeded the day before siRNA transfection. siRNAs targeting either 
SOX4 (Thermo Scientific oligo ID ROSJN-00001, ROSJN-00003) or TMEM2 
(Integrated DNA Technologies (IDT) siRNA identity HSC.RNAI.N013390.12.10, 
HSC.RNAI.N013390.12.2) and control siRNA (Thermo Scientific, siGENOME 
Control siRNA #1) were transfected with Lipofectamine reagent according to the 
manufacturer’s protocol. Forty-eight hours after transfection, the cells were 




Transcriptomic profiling (microarray) 
1 ug of total RNA extracted from two independent RNAi-mediated knockdown of 
SOX4 and two control cells was labeled and hybridized on Illumina BeadChip 
array (GPL10558_HumanHT-12_V4_0_R2_15002873_B) by the Genomics core 
facility at Rockefeller University. Heat maps depicting relative expression levels of 
genes from microarray data was created with matrix2png (Pavlidis and Noble, 
2003). For miRNA expression profiling, total RNA extracted from two independent 
stable knockdown of METTL3 and two control cells was labeled and hybridized on 
miRNA microarrays by LC sciences. The arrays have probes for all miRNAs of 
human (1872 precursors, 2578 mature) available in the miRBase database 
(Release 20). Of all the probes assayed, those corresponding to 438 miRNAs 
revealed a signal above background in at least two of the MDA-MB-231 cell lines. 
Analysis of mRNA expression 
Total RNA from cancer cells was extracted and purified using the mirVana 
(Applied Biosystems) or Total RNA Purification Kit (Norgen Biotek). mRNA 
expression quantification was performed as described previously (Png et al., 
2012). Refer to list of qRT-PCR primers in Appendix. 
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Chromatin immunoprecipitation sequencing (ChIP-Seq) 
2.2 × 107 cancer cells either expressing FLAG tagged SOX4 or control empty 
vector were harvested, washed with ice-cold PBS twice and flash-freeze in liquid 
nitrogen. The pellets were fixed with 1% paraformaldehyde (PFA) in PBS for 10 
min at room temperature with rotation. Glycine was added to a final concentration 
of 0.125 M to quench unreacted PFA and incubate for 5 min at room temperature. 
The fixed cells were lysed in ice-cold LB1 buffer containing 50 mM Hepes-KOH 
(pH 7.5), 140 mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Triton x-100, and 
protease inhibitors (Thermo Scientific, 78443). The pellet was washed with 
ice-cold LB2 buffer containing 10 mM Tris-HCl (pH 8.0), 200 mM NaCl, 1mM 
EDTA, 0.5 mM EGTA and protease inhibitors. The pellet was digested with 
micrococcal nuclease (MNase, Worthington) and further lysed with LB3 buffer 
containing 10 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 
0.1 % Na-Deoxycholate, 0.5 % N-lauroylsarconsine, 1 % Triton x-100, and 
protease inhibitors. The pellet was sonicated 60 times for 30 sec with intermediate 
incubation of 30 sec (Bioruptor, Diagenode). The lysate was incubated at 4°C for 
overnight with anti-FLAG M2 Magnetic Beads (M8823, Sigma). The 
immunoprecipitations were washed twice with the wash buffer containing 20 mM 
Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 1% Triton x-100 followed by last 
wash with TE buffer. Then eluted for 30 min at 65°C with the elution buffer 
containing 50 mM Tris-HCl (pH 8.0), 10 mM EDTA, 1% SDS. Crosslink was 
reversed for overnight at 65°C with shacking at a speed of 300 rpm (Eppendorf 
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Thermomixer 5350). RNA and protein digestions were performed sequentially by 
incubation with RNAse (Roche, 11-119-915-001) for 1 hour at 37°C and then with 
Proteinase K (Roche, 03-115-828-001) for 2 hours at 55°C with shacking at 300 
rpm. The DNA was recovered and purified by QIAquick PCR Purification Kit 
(Qiagen, 28104) and further processed for high-throughput sequencing with 
NEXTflex ChIP-Seq Kit (5143-01) according to the manufacturer’s protocol. 
Western Blotting 
Protein expression of FLAG tagged SOX4 was detected using anti-FLAG 
conjugated with HRP (A8592 Sigma) or SOX4 antibody generated from rabbits 
immunized with a synthetic peptide between 352 and 365 amino acids from the 
C-terminal region of human SOX4 (CGR SPA DHR GYA SLR). 
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Clinical correlation analysis 
The Cancer Genome Atlas (TCGA) Data: Expression levels of SOX4 and 
TMEM2 in TCGA Breast Invasive Carcinoma were obtained from cBioPortal for 
Cancer Genomics (www.cbioportal.org) and UCSC cancer browser 
(genome-cancer.ucsc.edu). Among 1098 patients, 1073 patients had stage 
information ranging from Stage I to Stage IV. Nonparametric Spearman 
correlation with one-tailed p-value are shown in figure. 
Expression Project for Oncology (ExpO) Data: Total of 236 breast 
cancer samples (4 of stage 0, 31 of stage 1, 129 of stage 2, 67 of stage 3, 5 of 
stage 4) were obtained from the ExpO microarray database (GSE2109) 
(http://www.intgen.org/research-services/biobanking-experience/expo/). 
Expression levels of SOX4 and the putative target genes were analyzed. 
Gene expression-based Outcome for Breast cancer Online (GOBO) 
Data: Assessment of gene expression levels and association with overall survival 
outcome for TMEM2 and SOX4 in breast cancer subgroups (stage 0, I, II, III, IV) 
were done by GOBO (http://co.bmc.lu.se/gobo/gobo.pl). 
Luciferase reporter assay 
The SOX4 bound regions of TMEM2 obtained from ChIP-qPCR were cloned into 
the pGL3-Promoter vector (Promega, E1761) that contains the Firefly luciferase 
gene downstream from a multiple cloning site into which the promoter of interest 
is inserted. These vectors (25 ng) were co-transfected with the Renilla luciferase 
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vector (2.5 ng) into HEK293T cells either transiently overexpressing FLAG tagged 
SOX4 (22.5 ng) or control empty plasmid (22.5 ng). After 30 hours post 
transfection, the cells were processed with Dual-Luciferase Reporter Assay 
System (Promega, E1910) according to the manufacturer’s protocol. Luciferase 
activities were measured in a luminometer and the Firefly luciferase activity was 
normalized to the Renilla luciferase activity. 
Trans-well invasion assay 
The trans-well invasion assays were performed as described previously 
(Tavazoie et al., 2008). Cells were incubated overnight in the culture media with 
low concentrations of FBS (0.2%). The next day, the cells were trypsinized, 
re-suspended in the low serum media, and seeded at 5 × 104 cells per well into 
growth factor reduced matrigel invasion chambers (8 µm pore size, BD 
Biosciences). After 22hours, the chambers were washed with PBS twice and the 
cells on the apical side of each inserts were scraped off. The invaded cells fixed 
with 4% paraformaldehyde were stained with DAPI and quantified with ImageJ. 
Trans-well migration assay 
Trans-well migration assays were performed as described previously (Tavazoie et 
al., 2008) with minor modifications: cells were incubated with low concentrations 
of FBS (0.2%) for overnight and then seeded at 1 × 105 cells per cell-culture insert 
made of Track-etched polyethylene terephthalate (PET) membranes with pores (3 
µm pore size, BD Biosciences). After 12hours, the migrated cells were stained 
with DAPI and quantified with ImageJ. 
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Animal Studies 
All animal work has conducted in accordance with a protocol approved by the 
Institutional Animal Care and Use Committee (IACUC) at The Rockefeller 
University. NOD scid gamma female mice (The Jackson Laboratory) 
age-matched between six and eight weeks were used for tail-vein injection. 
Statistical Data Analysis 
All data are represented as mean ± standard error of mean (SEM) with p-values: 
**** 𝑃 < 1×10!!, *** 𝑃 < 5×10!!, ** 𝑃 < 1×10!!, * 𝑃 < 5×10!!. One-tailed 
Student’s t test was used and 𝑃 < 1×10!! was considered to be statistically 
significant. 
qRT-PCR for miRNAs 
Mature miRNAs were quantified by either Taqman microRNA assays (Applied 
Biosystems) or poly-A tailing of total RNA followed by reverse-transcriptase (RT) 
reaction with T7 oligo dT (NEB). Quantitative miRNA expression data were 
acquired and analyzed using an ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems). Pri-miRNAs were measured using the TaqMan Pri-miRNA 
Assay. RNU44, GusB, GAPDH and 18S were used as endogenous controls. 
m6A Immunoprecipitation and RNA seq 
3 × 107 cells/sample were lysed using LB1 buffer (50 mM Hepes-KOH pH 7.5, 140 
mM NaCl, 1 mM EDTA, 10% glycerol, 0.5% Triton x-100, and protease inhibitors). 
The nuclear fraction was then lysed with M-PER buffer and diluted 10-fold in 
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dilution buffer before the immunoprecipitation. Rabbit a-m6A antibody (Synaptic 
Systems) and rabbit IgG control bound to protein A Dynabeads were used for the 
immunoprecipitations. The immunoprecipitated RNA was eluted with 
N6-methyladenosine (Sigma-Aldrich), ethanol precipitated and resuspended in 
water. RNA was barcoded using ScriptSeq V2 kit (Epicentre) and sent for 
sequencing. 
m6A analysis 
Paired reads were mapped to the human genome (build hg19) using bowtie2 with 
“sensitive-local” option. Consistent paired reads were converted into genomic 
intervals (bed format). ChIPseeqer was used to detect statistically significant 
peaks that were present in the m6A co-precipitation samples and not the IgG 
control. The following parameters were used: -t 10 -fold_t 2 -min len 20. FIRE was 
used for non-discovery analysis, and ChIPseeqer was used for shuffled 
sequences. 
HITS-CLIP 
We performed HITS-CLIP as previously described (Zhang and Darnell, 2011) with 
some modifications. After UV crosslinking (400mJ/cm2 of 254nm UV), we isolated 
nuclear fractions from 3x107 cells/sample using LB1 buffer. The nuclear fraction 
was then lysed in M-PER buffer (Thermo Scientific) and diluted 10 fold in a buffer 
containing 50 mM Tris-HCl pH 7.4 and 100mM NaCl, before the 
immunoprecipitation. For the endogenous immunoprecipitation we used 3ug of 
a-METTL3 rabbit antibody (Bethyl) or rabbit IgG as control bound to protein A 
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dynabeads (Invitrogen). For Flag immunoprecipitation we used cells 
overexpressing Flag-METTL3 or cells without a Flag-tagged protein as the control 
and used anti-Flag magnetic beads (Sigma). After the immunoprecipitation a 
32P-labeled linker was ligated to the RNA on the beads. The samples were 
resolved using SDS-PAGE, transferred to nitrocellulose membrane and exposed 
overnight. The films were used to guide the cut of the membrane to extract the 
radiolabeled RNA. RNA was extracted in 200ul of PK buffer containing proteinase 
K (4mg/ml), then adding 200ul of PK buffer containing 7M urea and lastly 400 ul of 
acid phenol:chloroform, each step 20 min at 37°C at 1,000 rpm shaking 
(Eppendorf Thermomixer 5350). The aqueous solution was then precipitated and 
resuspended in RNase-free water as described in the in vitro processing section. 
An RNA linker was ligated to the purified RNA at 16°C overnight. The RNA was 
once again extracted using phenol:chloroform and precipitated as previously 
described. This new RNA was reverse transcribed and PCR enriched. These PCR 
amplicons were resolved in a TBE-Urea poly-acrylamide gel and DNA between 90 
and 140 bp was extracted. This DNA was further enriched with the addition of 
Solexa fusion primers and the product was resolved in a 2% metaphor 
agarose/TBE gel, from which and a DNA between 150-170 bp was extracted. The 
samples were submitted for high throughput sequencing using an Illumina HiSeq 




The reads were trimmed and clipped using cutadapt (v1.2.1) and were 
subsequently mapped to the human genome (build hg19) using bowtie. CIMS 
package was used to detect CLIP clusters with cross-linking induced mutations. 
FIRE was used for non-discovery analysis, and ChIPseeqer for shuffled 
sequences. 
 
Density plots analysis 
The distance between peaks located in introns to closest miRNAs were measured 
using closestBed. In R, ggplot was used to generate the density plots. 
 
Co-Immunoprecipitations 
Cells were lysed with LB1 and the nuclear fraction was then lysed with M-PER 
buffer (Thermo Scientific) and diluted 10-fold in dilution buffer. 
Immunoprecipitations were performed with a-METTL3 rabbit antibody (Bethyl) or 
a-DGCR8 rabbit antibody (Abcam), previously bound to magnetic Dynabeads 
Protein A (Life Technologies), in the presence with either RNase A or RNase 
inhibitor (Promega). The immunoprecipitations were washed twice with high-salt 
buffer (50 mM Tris-HCl pH 7.4, 300 mM NaCl) followed by two times more wash 
with low-salt buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl). The following 
antibodies were used for western blot analysis a-METTL3 (mouse, Novus 
Biologicals), a-DGCR8 (mouse, Abcam), a-m6A (mouse, Synaptic Systems).  
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For the in vitro binding assay once DGCR8 was immunopurified and still bound to 
the magnetic beads it was incubated with 1ug of pri-let-7e and 200ng of 
pri-miR-1-1, in the presence of RNAse inhibitors for 20 min at room temperature, 
washed twice and eluted with 170 ul of RNA elution buffer (0.3 M sodium acetate, 
pH 5.5 and 2% SDS). RNA was then extracted with 200ul of acid 
phenol:chloroform, precipitated and resuspended in RNase-free as described in 
the in vitro processing section. An aliquot of the elution was then used for northern 
blot analysis. 
For the radiolabeled experiments the cells were UV-crosslinked, the nuclear 
fraction was lysed with M-PER buffer and diluted 10-fold in dilution buffer. The 
nuclear extracts were immunoprecipitated with a-DGCR8 antibody or IgG as 
control. A RNA oligo was labeled with 32P-gamma-ATP (Perkin Elmer) and ligated 
to the co-immunoprecipitated RNA as in the HITS-CLIP protocol. The samples 
(triplicates) were loaded in a SDS-PAGE, transferred, and the membrane was 
exposed overnight or longer if needed. After the image of the radiolabeled RNA 
was obtained, the same membrane was immunoblotted for DGCR8 for 
normalization. Quantitation was achieved using ImageJ. 
For the endogenous DGCR8-pri-miRNA binding experiments, similar to the 
radiolabeled experiments, the cells were UV-crosslinked and the nuclear fraction 
was lysed with M-PER buffer and diluted in dilution buffer. The nuclear extracts 
were immunoprecipitated with an anti-DGCR8 antibody or IgG as a control. The 
RNA was extracted by treatment with 200 ul of proteinase K (4mg/ml) in PK buffer 
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(100mM Tris-Cl pH 7.5, 50mM NaCl and 10mM EDTA) and incubation at 37°C for 
20 min with shaking. Then, 200ul 7M urea in PK buffer was added and incubated 
20 min more at 37°C with shaking. After that 400ul acid phenol:chloroform 
(Ambion) was added to the solution, vortexed and centrifuged at maximum speed 
for 5 min.The aqueous phase was precipitated with 50ul 3M NaOAc pH 5.2, 
0.75ul glycoblue and 1mL of 1:1 ethanol:isopropanol at -20°C at least 30 min. The 
mix was then centrifuged at 4°C at maximum speed for 15 min, and the pellet 
washed with 80% ethanol and air-dried. The RNA was resuspended in 20ul of 
RNase-free water and 8 ul were used to produce cDNA by ramdom hexamers 
(SuperScript III First-Strand Synthesis System, Life Technologies) and qRT-PCR 
was carried out using specific miRNA primers. 
 
Northern Blots 
Non-radioactive northern blots were performed as previously described (Kim et 
al., 2010). RNA was extracted with miRVana or Norgen Biotek RNA extraction 
kits. DIG-labeled LNA probes against let-7e and miR-1-1 were obtained from 
EXIQON. Pre-stained marker (DynaMarker) was obtained from BioDynamics 
Laboratory Inc and Low range ssRNA Ladder from NEB. Mini-protean 10% and 
15% pre-cast TBE-Urea gels were purchased from Bio-RAD and TBE buffer from 
Invitrogen. Samples were prepared using 2x Gel loading buffer (Ambion) and 
denatured 5min at 95C. Gels were at 200V in 1X TBE buffer and then transfered 
to a nylon membrane at 80V for 1 hour in 0.5X TBE buffer. Membranes were 
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either chemically crosslinked with EDC (0.753g of 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in 24ml of 125mM solution of 
1-methylimidazole pH of 8.0) for mature and pre-miRNAS (2 hours at 65C) or UV 
crosslinking for pri-miRNAs (240 mJoules). The membrane was then pretreated 
with hybridization buffer (DIG Easy Hyb Granules, Roche) at 37°C for at least 30 
min in hybridization oven. The probe was denatured at 95°C for 1 min and added 
to the hybridization buffer (37°C overnight). The membrane was washed twice 
with Low Stringent Buffer at 37°C for 15 min, twice with High Stringent Buffer at 
37°C for 5 min. and once with Washing Buffer at 37°C for 10 min. Then the 
membrane was incubated in Blocking Buffer (DIG Wash and block buffer set, 
Roche) for 3 hours at room temperature and the anti-Digoxigenin-AP antibody 
(Roche) was added (1:15,000 dilution) and incubated at room temperature for an 
extra 30 min. The membrane was washed in DIG Washing buffer four times for 15 
min each at room temp. Finally the membrane was incubated in development 




In vitro pri-miRNA processing 
Pri-miRNAs were in vitro transcribed using the T7 based MEGAshortscript kit (Life 
Technologies) according to the manufacture’s indications. In cases were m6A 
modifications were added in vitro, N6-methyl-ATP (tri-link) was used in a ratio 4:1 
to ATP in the in vitro transcription reaction. Pri-miRNA processing reactions were 
performed as previously described (Lee and Kim, 2007). In brief, 293 cells were 
co-transfected plasmids carrying DROSHA and DGCR8 (obtained from Addgene). 
48 hours later, cells were lysed in lysis buffer (20 mM Tris-HCl pH 8.0, 100 mM 
KCl, and 0.2 mM EDTA) and sonicated for 1 min with 5 sec pulses at 30% 
amplitude. The whole cell was obtained after centrifugetion at 13,523 rcf at 4°C for 
15 min. In the case of testing the effect of METTL3 depletion on pri-miRNA 
processing, cells were not transfected and the endogenous activity was 
measured. The in vitro processing reaction contained 3 ul of 64 mM MgCl2 
solution, 1 ug of Let-7e pri-miRNA (wildtype or m6A methylated), 50ng of control 
pri-miR-1-1, 0.75 ul of RNase inhibitor, 15 ul of HEK293T whole extract and 
RNase-free water to a final volume of 30 ul. The reactions were incubated at 37°C 
for 90 min. Then 170 ul of RNA elution buffer (0.3 M sodium acetate, pH 5.5 and 
2% SDS) was added to the reaction to dissociate the RNA from the proteins and 
terminate the reaction. RNA was then extracted with 200 ul of acid 
phenol:chloroform (Ambion), vortexed and centrifuged for 5 min at room 
temperature. After extraction the RNA was precipitated at -20°C by adding 20 ul of 
sodium acetate (3M), 1 ul of glycoblue (Life Technologies), and 800 ul of a mix 
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isopropanol:ethanol (1:1). The mix was then centrifuged at 4°C at maximum 
speed for 15 min, and the pellet washed with 80% ethanol and air-dried. The RNA 




Analysis of pri-miRNA processing using ectopic reporter constructs was 
performed as previously described (Auyeung et al., 2013). We used the 
pri-miRNA reporter construct developed by Bartel and collegues (Auyeung et al., 
2013) and replaced the miRNA control pri-miR-1-1 with a mutant version in which 
the adenosines of the potential METTL3 motifs were mutated. Then we placed the 
query miRNA, either wildtype pri-let-7e or its altered version in which the A's of the 
putative METTL3 motifs were mutated to T's, upstream of the pri-miR-1-1 control. 
We then used these two constructs to transfect HEK293T cells using 
Lipofectamine 2000. 48 hours later the RNA was extracted and qRT-PCR was 
performed to test the production of mature let-7e and mature miR-1-1. 
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APPENDIX – LIST OF QRT-PCR AND CLONING PRIMERS 
QRT-PCR primers 
QRT-PCR primers 
Gene FWR primer REV primer Amplicon size (bp) 
18S gtaacccgttgaaccccatt ccatccaatcggtagtagcg 151 
GAPDH agccacatcgctcagacac gcccaatacgaccaaatcc 66 
SOX4 gaaggtgaagtccggcaac accgaccttgtctcccttct 82 
BCAR3 ctgcgcctggacataattg gctcggtcctccaaagtg 92 
PFKFB3 ttggcgtccccacaaaagt agttgtaggagctgtactgctt 75 
RPH3AL ctggagcagcagagaatcg ccgttccccatcacattc 71 
SLC3A2 gtgctgggtccaattcacaag caccccggtagttgggagta 166 
SPANXA2 cgaggccaacgagatgat tggtcgaggactcagatgttt 92 
TMEM2 ttcagggtggtcagaacaagt aagcctctaattgggaacgtc 94 
TMEM2_pre-mRNA gtcctcctccttgttgtgga aaaatcggacttgaccaggc 207 
ChIP-qPCR primers 
GAPDH_promoter tactagcggttttacgggcg tcgaacaggaggagcagagagcga 166 
TMEM2_promoter_#3 ctggtactgcgcctgtca atatttattccggcctgcgag 300 
TMEM2_promoter_#4 agctcttctggtcccttgga agtcctgcagctgtcactag 321 
TMEM2_promoter_#6 ctagtgacagctgcaggact gtagattgcgcgacgtctg 323 
TMEM2_promoter_#7 agtcctgtaaccgcgacac ctttcctccctgcctatccc 349 
TMEM2_promoter_#12 ctgtgctgggccaactttat cgcctggcctaattgctatt 257 
TMEM2_promoter_#13 ttcccaaggccacacagtaa caccttccttagcctcccaa 131 
 
Cloning primers 
N-terminal FLAG tagged SOX4 
EcoRI-FLAG-huSox4 gggggaattcatggattacaaggatgacgacgataaggtgcagcaaaccaacaatgc 
huSox4-SalI gggggtcgactcagtaggtgaaaaccaggt 
C-terminal V5 tagged TMEM2 
Mutagenic primers to fix TMEM2 C-terminal frame-shift point mutation present in the ORFeome library 
t3928g_antisense gatgagctggtttggctaatcccagaggtactagt 
t3928g_sense actagtacctctgggattagccaaaccagctcatc 
Gateway cloning to pDONR221 vector 
12attB1_TMEM2 aaaaagcaggcttcaccatgtatgccactgattccag 
12attB2_TMEM2_C-term agaaagctgggtgcaaatgtgcttttgaagctt 
Universal attB1_adapter ggggacaagtttgtacaaaaaagcaggct 
Universal attB2_adapter ggggaccactttgtacaagaaagctgggt 
Clone TMEM2 promoter region into pGL3 Promoter Luciferase vector 
MluI_-1kb_F gatacgcgtacacctttggaccatgaaaaca 
XhoI_-1kb_R gatgctcgagatccgggccgtcgtcatc 
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